Transgender Patients: Providing Sensitive Care

Article Type
Changed
Thu, 03/28/2019 - 14:56
Display Headline
Transgender Patients: Providing Sensitive Care

 

Civil rights for the lesbian, gay, bisexual, and transgender population have advanced markedly in the past decade, and the medical community has gradually begun to address more of their health concerns. More recently, media attention to transgender individuals has encouraged many more to openly seek care.1,2

It is estimated that anywhere from 0.3% to 5% of the US population identifies as transgender.1-3 While awareness of this population has slowly increased, there is a paucity of research on the hormone treatment that is often essential to patients’ well-being. Studies of surgical options for transgender patients have been minimal, as well.

Primary care providers are uniquely positioned to coordinate medical services and ensure continuity of care for transgender patients as they strive to become their authentic selves. Our goal in writing this article is to equip you with the tools to provide this patient population with sensitive, high-quality care (see Table 1).4-7 Our focus is on the diagnosis of gender dysphoria (GD) and its medical and hormonal management—the realm of primary care providers. We briefly discuss surgical management of GD, as well.

UNDERSTANDING AND DIAGNOSING GENDER DYSPHORIA

Two classification systems are used for diagnoses related to GD: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed (DSM-5)8 and the International Classification of Diseases, 10th Rev (ICD-10).9

ICD-10 criteria use the term gender identity disorder; DSM-5 refers to gender dysphoria instead. It is important to emphasize that these classification systems represent an attempt to categorize a group of signs and symptoms that lead to distress for the patient and are not meant to suggest that being transgender is pathological. In fact, in DSM-5—released in 2013—the American Psychiatric Association revised the terminology to emphasize that such individuals are not “disordered” by the nature of their identity, but rather by the distress that being transgender causes.8

For a diagnosis of GD in children, DSM-5 criteria include characteristics perceived to be incongruent between the child’s sex at birth and the self-identified gender based on preferred activities or dislike of his or her own sexual anatomy. The child must meet six or more of the following for at least six months

  • A repeatedly stated desire to be, or insistence that he or she is, of the other gender
  • In boys, a preference for cross-dressing or simulating female attire; in girls, insistence on wearing only stereotypical masculine clothing
  • Strong and persistent preferences for cross-gender roles in make-believe play or fantasy
  • A strong rejection of toys/games typically associated with the child’s sex
  • Intense desire to participate in stereotypical games and pastimes of the other gender
  • Strong preference for playmates of the other gender
  • A strong dislike of one’s sexual anatomy
  • A strong desire for the primary (eg, penis or vagina) or secondary (eg, menstruation) sex characteristics of the other gender.8

Adolescents and adults must meet two or more of the following for at least six months

  • A noticeable incongruence between the gender that the patient sees themselves as and their sex characteristics
  • An intense need to do away with (or prevent) his or her primary or secondary sex features
  • An intense desire to have the primary and/or secondary sex features of the other gender
  • A deep desire to transform into another gender
  • A profound need for society to treat them as someone of the other gender
  • A powerful assurance of having the characteristic feelings and responses of the other gender.8

For children as well as adolescents and adults, the condition should cause the patient significant distress or significantly affect him or her socially, at work or school, and in other important areas of life.8

 

 

 

Is the patient a candidate for hormone therapy?

Two primary sources—Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7, issued by the World Professional Association for Transgender Health (WPATH)10 and Endocrine Treatment of Transsexual Persons11 by the Endocrine Society—offer clinical practice guidance based on evidence and expert opinion.

WPATH recommends that a mental health professional (MHP) experienced in transgender care diagnose GD to ensure that it is not mistaken for a psychiatric condition manifesting as altered gender identity. However, if no one with such experience is available or accessible in the region, it is reasonable for a primary care provider to make the diagnosis and consider initiating hormone therapy without a mental health referral,12 as the expected benefits outweigh the risks of nontreatment.13

Whether or not an MHP confirms a diagnosis of GD, it is still up to the treating provider to confirm the patient’s eligibility and readiness for hormone therapy: He or she should meet DSM-5 or ICD-10 criteria for GD, have no psychiatric comorbidity (eg, schizophrenia, body dysmorphic disorder, or uncontrolled bipolar disorder) likely to interfere with treatment, understand the expected outcomes and the social benefits and risks, and have indicated a willingness to take the hormones responsibly.

Historically, patients were required to have a documented real-life experience, defined as having fully adopted the new gender role in everyday life for at least three months.10,11 This model has fallen out of favor, however, as it is unsupported by evidence and may place transgender individuals at physical and emotional risk. Instead, readiness is confirmed by obtaining informed consent.12

Puberty may be suppressed with a gonadotropin-releasing hormone (GnRH) agonist in adolescents who have a GD diagnosis and are at Tanner stage 2 to 3 of puberty until age 16. At that point, hormone therapy consistent with their gender identification may be initiated (see “How to Help Transgender Teens”).11

 

 

 

Beginning the transition

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

For patients interested in medical interventions, possible therapies include cross-sex hormone administration and gender-affirming surgery. Both are aimed at making the physical and the psychologic more congruent. Hormone treatment (see Table 2) is often essential to reduce the distress of individuals with GD and to help them feel comfortable in their own body.10,11,21 Psychologic conditions, such as depression, tend to improve as the transitioning process gets underway.22

FEMALE-TO-MALE TRANSITION

CASE 1 Jennie R, a 55-year-old postmenopausal patient, comes to your office for an annual exam. Although you’ve been her primary care provider for several years, she confides for the first time that she has never been comfortable as a woman. “I’ve always felt that my body didn’t belong to me,” the patient admits, and goes on to say that for the past several years she has been living as a man. Jennie R says she is ready to start hormone therapy to assist with the gender transition and asks about the process, the benefits and risks, and how quickly she can expect to achieve the desired results.

If Jennie R were your patient, how would you respond?

Masculinizing hormone treatment

As you would explain to a patient like Jennie R, the goal of hormone therapy is to suppress the effects of the sex assigned at birth and replace them with those of the desired gender. In the case of a female transitioning to a male (known as a transman), masculinizing hormones would promote growth of facial and body hair, cessation of menses, increased muscle mass, deepening of the voice, and clitoral enlargement.11,23,24

Physical changes induced by masculinizing hormone therapy have an expected onset of one to six months and achieve maximum effect in approximately two to five years.10,11 Although there have been no controlled clinical trials evaluating the safety or efficacy of any transitional hormone regimen, WPATH and the Center of Excellence for Transgender Health at the University of California, San Francisco, suggest initiating intramuscular or transdermal testosterone at increasing doses until normal physiologic male testosterone levels between 350 and 700 ng/dL are achieved, or until cessation of menses.13,25-28 The dose at which either, or both, occur should be continued as long-term maintenance therapy. Medroxyprogesterone can be added, if necessary for menstrual cessation, and a GnRH agonist or endometrial ablation can be used for refractory uterine bleeding.29,30

Testosterone is not a contraceptive. It is important to emphasize to transmen like Jennie that they remain at risk for pregnancy if they are having sex with fertile males. Caution patients not to assume that the possibility of pregnancy ends when menses stop.

Treat minor adverse effects. Adverse effects of masculinizing hormones include vaginal atrophy, fat redistribution and weight gain, polycythemia, acne, scalp hair loss, sleep apnea, elevated liver enzymes, hyperlipidemia, cardiovascular disease, diabetes, and bone density loss. Increased risk for cancer of the female organs has not been proven.10,11 It is reasonable to treat minor adverse effects after reviewing the risks/benefits of doing so, as discontinuing hormone therapy could be detrimental to the well-being of transitioning patients.11

There are absolute contraindications to masculinizing hormone therapy, however, including pregnancy, unstable coronary artery disease, and untreated polycythemia with a hematocrit > 55%.10

Monitoring is essential. Patients receiving masculinizing hormone therapy should be monitored every three months during the first year and once or twice a year there­after, with a focused history (including mood symptoms), physical exam (including weight and blood pressure), and labs (including complete blood count, liver function, renal function, and lipids) at each visit.11,23 Some clinicians also check estradiol levels until they fall below 50 pg/mL,23,27 while others take the cessation of uterine bleeding for > 6 months as an indicator of estrogen ­suppression.

Preventive health measures continue. Routine screening should continue, based on the patient’s assigned sex at birth. Thus, a transman who has not had a hysterectomy still needs Pap smears, mammograms if the patient has not had a double mastectomy, and bone mineral density (BMD) testing to screen for osteoporosis.31,32 Some experts recommend starting to test BMD at age 50 for patients receiving masculinizing hormones, given the unknown effect of testosterone on bone density.11,31,32

CASE 1 The first question for a transgender patient is about his or her current gender identity, but Jennie R has already reported living as a man. So you start by asking “What name do you prefer to use?” and “Do you prefer to be referred to with male or female pronouns?”

 

 

 

The patient tells you that he sees himself as a man, he wants to be called Jeff, and he prefers male pronouns. You explain that you believe he has gender dysphoria and would benefit from hormone therapy, but it is important to confirm this diagnosis with an MHP. You explain that testosterone can be prescribed for masculinizing effects, and describe the expected effects—more facial and body hair, a deeper voice, and greater muscle mass, among others—and review the likely time frame.

You also discuss the risks of masculinizing hormones (hyperlipidemia, cardiovascular disease, diabetes, and loss of bone density) that will need to be monitored. Before he leaves, you give him the name of an MHP who is experienced in transgender care and tell him to make a follow-up appointment with you after he has seen her. At the conclusion of the visit, you make a note of the patient’s name and gender identity in the chart and inform the staff of the changes.

MALE-TO-FEMALE TRANSITION

CASE 2 Before heading into your office to talk to a new patient named Carl S, you glance at his chart and see that he is a healthy 21-year-old who has come in for a routine physical. When you enter the room, you find Carl wearing a dress, heels, and make-up. After confirming that you have the right patient, you ask, “What is your current gender identity?” “Female,” says Carl, who indicates that she now goes by Carol. The patient has no medical problems, surgical history, or significant family history but reports that she has been taking spironolactone and estrogen for the past three years. Carol also says she has a new female partner and is having unprotected sexual activity.

Feminizing hormone treatment

The desired effects of feminizing hormones include voice change, decreased hair growth, breast growth, body fat redistribution, decreased muscle mass, skin softening, decreased oiliness of skin and hair, and a decrease in spontaneous erections, testicular volume, and sperm production.10,11 The onset of feminizing effects ranges from one month to one year and the expected maximum effect occurs anywhere between three months and five years.10,11 Regimens usually include anti-androgen agents and estrogen.13,26-28

The medications that have been most studied with anti-androgenic effects include spironolactone and 5-α reductase inhibitors (5-ARIs) such as finasteride. Spironolactone inhibits testosterone secretion and inhibits androgen binding to androgen receptors; 5-ARIs block the conversion of testosterone to 5-α-dihydrotestosterone, the more active form.

Estrogen can be administered via oral, sublingual, transdermal, or intramuscular route, but parenteral formulations are preferred to avoid first-pass metabolism. The serum estradiol target is similar to the mean daily level of premenopausal women (< 200 pg/mL) and the level of testosterone should be in the normal female range (< 55 ng/dL).13,26-28

The selection of medications should be individualized for each patient. Comorbidities must be considered, as well as the risk for adverse effects, which include venous thromboembolism, elevated liver enzymes, breast cancer, cardiovascular disease, diabetes, hyperprolactinemia, weight gain, gallstones, cerebrovascular disease, and severe migraine headaches.10,11 Estrogen therapy is not reported to induce hypertrophy or premalignant changes in the prostate.33 As is the case for masculinizing hormones, feminizing hormone therapy should be continued indefinitely for long-term effects.

Frequent monitoring is recommended. Patients taking feminizing hormones (transwomen) should be seen every two to three months in the first year and monitored once or twice a year thereafter. Serum testosterone and estradiol levels should initially be monitored every three months; serum electrolytes, specifically potassium, should be monitored every two to three months in the first year until stable.

 

 

 

CASE 2 You recommend that Carol S be screened annually for sexually transmitted diseases, as you would for any 21-year-old patient. You point out, too, that while estrogen and androgen-suppressing therapy decrease sperm production, there is a possibility that the patient could impregnate a female partner and recommend that contraception be used if the couple is not trying to conceive.

You also discuss the risks and benefits of hormone therapy and reasonable expectations of continued treatment. You ask Carol to schedule a follow-up visit in six months, as her hormone regimen is stable. Finally, if the patient remains on hormone therapy, you mention that the only screening unique to men transitioning to women is for breast cancer, which should begin at age 40 to 50 (as it should for all women).

Gender-affirming surgical options

Surgical management of transgender patients is not within the scope of family medicine. But it is essential to know what procedures are available, as you may have occasion to advocate for patients during the surgical referral process and possibly to provide postoperative care.

For transmen, surgical options include chest reconstruction, hysterectomy/oophorectomy, metoidioplasty (using the clitoris to surgically approximate a penis), phalloplasty, scrotoplasty, urethroplasty, and vaginectomy.10,34 The surgeries available for transwomen are orchiectomy, vaginoplasty, penectomy, breast augmentation, thyroid chondroplasty and voice surgery, and facial feminization.10,34 Keep in mind that not all transgender individuals desire surgery as part of the transitioning process.
 

The authors would like to acknowledge the assistance of Michelle Forcier, MD, MPH, and Karen S. Bernstein, MD, MPH, in the preparation of this manuscript.

References

 

 

1. Pew Research Center. A survey of LGBT Americans: attitudes, experiences and values in changing times. www.pewsocialtrends.org/2013/06/13/a-survey-of-lgbt-americans. Accessed January 13, 2017.
2. Gates GJ. How many people are lesbian, gay, bisexual and transgender? http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf. Accessed January 13, 2017.
3. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav. 1996;25:589-600.
4. Bhola S. An ally’s guide to terminology: talking about LGBT people & equality. www.glaad.org/2011/07/28/an-allys-guide-to-terminology-talking-about-lgbt-people-equality. Accessed January 13, 2017.
5. University of California, San Francisco. Transgender terminology. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/tcoe?page=protocol-terminology. Accessed January 13, 2017.
6. Istar A. How queer! The development of gender identity and sexual orientation in LGBTQ-headed families. Fam Process. 2010;49:268-290.
7. Goins ES, Pye D. Check the box that best describes you: reflexively managing theory and praxis in LGBTQ health communication research. Health Commun. 2013;28:397-407.
8. American Psychiatric Association. Gender dysphoria. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013: 451-459.
9. World Health Organization.  The International Classification of Diseases, 10th rev. Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992; Geneva.
10. Coleman E, Bockting W, Botzer M, et al; World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgender. 2011; 13:165-232.
11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endo Metabol. 2009;94:3132-3154.
12. University of California, San Francisco. Assessing readiness for hormones. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/tcoe?page=protocol-hormone-ready. Accessed January 13, 2017.
13. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):S31-S36.
14. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20:725-732.
15. Gay, Lesbian, and Straight Education Network (GLSEN). Harsh realities. The experiences of transgender youth in our nation’s schools. www.glsen.org/sites/default/files/Harsh%20Realities.pdf. Accessed January 13, 2017.
16. Berman M, Balingit M. Eleven states sue Obama administration over bathroom guidance for transgender students. May 25, 2016. Washington Post. www.washingtonpost.com/news/post-nation/wp/2016/05/25/texas-governor-says-state-will-sue-obama-administration-over-bathroom-directive/. Accessed January 13, 2017.
17. de Vries AL, Cohen-Kettenis PT, Delemarre-van de Waal H. Clinical management of gender dysphoria in adolescents. 2006. Vancouver Coastal Health - Transgender Health Program. www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf. Accessed January 13, 2017.
18. TransYouth Family Allies. Empowering transgender youth & families. www.imatyfa.org/. Accessed January 13, 2017.
19. Human Rights Campaign. On our own: a survival guide for independent LGBTQ youth. www.hrc.org/resources/on-our-own-a-survival-guide-for-independent-lgbtq-youth. Accessed January 13, 2017.
20. Gay, Lesbian, Bisexual, and Transgender National Help Center. www.glbthotline.org. Accessed January 13, 2017.
21. University of California, San Francisco. Hormone administration. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-hormones. Accessed January 13, 2017.
22. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013;201:996-1000.
23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
24. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20-28.
25. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008; 5:765-776.
26. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59:409-418.
27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-3473.
28. Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12-21.
29. Dickersin K, Munro MG, Clark M, et al. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2007;110:1279-1289.
30. Prasad P, Powell MC. Prospective observational study of Thermablate Endometrial Ablation System as an outpatient procedure. J Minim Invasive Gynecol. 2008;15:476-479.
31. University of California, San Francisco. General prevention and screening. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-screening. Accessed January 13, 2017.
32. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995; 82:341.
33. Meriggiola MC, Gava G. Endocrine care of transpeople part II: a review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83:607-615. 
34. University of California, San Francisco. Surgical options. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-surgery. Accessed January 13, 2017.

Article PDF
Author and Disclosure Information

Abbas Hyderi, Joseph Angel, Morgan Madison, L. Amanda Perry, and Leila Hagshenas are with the University of Illinois at Chicago.

The authors reported no potential conflict of interest relevant to this article.

This article originally appeared in The Journal of Family Practice (2016;65[7]:450-452, 457-461).

Issue
Clinician Reviews - 27(2)
Publications
Topics
Page Number
28-32,40-41,52
Sections
Author and Disclosure Information

Abbas Hyderi, Joseph Angel, Morgan Madison, L. Amanda Perry, and Leila Hagshenas are with the University of Illinois at Chicago.

The authors reported no potential conflict of interest relevant to this article.

This article originally appeared in The Journal of Family Practice (2016;65[7]:450-452, 457-461).

Author and Disclosure Information

Abbas Hyderi, Joseph Angel, Morgan Madison, L. Amanda Perry, and Leila Hagshenas are with the University of Illinois at Chicago.

The authors reported no potential conflict of interest relevant to this article.

This article originally appeared in The Journal of Family Practice (2016;65[7]:450-452, 457-461).

Article PDF
Article PDF

 

Civil rights for the lesbian, gay, bisexual, and transgender population have advanced markedly in the past decade, and the medical community has gradually begun to address more of their health concerns. More recently, media attention to transgender individuals has encouraged many more to openly seek care.1,2

It is estimated that anywhere from 0.3% to 5% of the US population identifies as transgender.1-3 While awareness of this population has slowly increased, there is a paucity of research on the hormone treatment that is often essential to patients’ well-being. Studies of surgical options for transgender patients have been minimal, as well.

Primary care providers are uniquely positioned to coordinate medical services and ensure continuity of care for transgender patients as they strive to become their authentic selves. Our goal in writing this article is to equip you with the tools to provide this patient population with sensitive, high-quality care (see Table 1).4-7 Our focus is on the diagnosis of gender dysphoria (GD) and its medical and hormonal management—the realm of primary care providers. We briefly discuss surgical management of GD, as well.

UNDERSTANDING AND DIAGNOSING GENDER DYSPHORIA

Two classification systems are used for diagnoses related to GD: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed (DSM-5)8 and the International Classification of Diseases, 10th Rev (ICD-10).9

ICD-10 criteria use the term gender identity disorder; DSM-5 refers to gender dysphoria instead. It is important to emphasize that these classification systems represent an attempt to categorize a group of signs and symptoms that lead to distress for the patient and are not meant to suggest that being transgender is pathological. In fact, in DSM-5—released in 2013—the American Psychiatric Association revised the terminology to emphasize that such individuals are not “disordered” by the nature of their identity, but rather by the distress that being transgender causes.8

For a diagnosis of GD in children, DSM-5 criteria include characteristics perceived to be incongruent between the child’s sex at birth and the self-identified gender based on preferred activities or dislike of his or her own sexual anatomy. The child must meet six or more of the following for at least six months

  • A repeatedly stated desire to be, or insistence that he or she is, of the other gender
  • In boys, a preference for cross-dressing or simulating female attire; in girls, insistence on wearing only stereotypical masculine clothing
  • Strong and persistent preferences for cross-gender roles in make-believe play or fantasy
  • A strong rejection of toys/games typically associated with the child’s sex
  • Intense desire to participate in stereotypical games and pastimes of the other gender
  • Strong preference for playmates of the other gender
  • A strong dislike of one’s sexual anatomy
  • A strong desire for the primary (eg, penis or vagina) or secondary (eg, menstruation) sex characteristics of the other gender.8

Adolescents and adults must meet two or more of the following for at least six months

  • A noticeable incongruence between the gender that the patient sees themselves as and their sex characteristics
  • An intense need to do away with (or prevent) his or her primary or secondary sex features
  • An intense desire to have the primary and/or secondary sex features of the other gender
  • A deep desire to transform into another gender
  • A profound need for society to treat them as someone of the other gender
  • A powerful assurance of having the characteristic feelings and responses of the other gender.8

For children as well as adolescents and adults, the condition should cause the patient significant distress or significantly affect him or her socially, at work or school, and in other important areas of life.8

 

 

 

Is the patient a candidate for hormone therapy?

Two primary sources—Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7, issued by the World Professional Association for Transgender Health (WPATH)10 and Endocrine Treatment of Transsexual Persons11 by the Endocrine Society—offer clinical practice guidance based on evidence and expert opinion.

WPATH recommends that a mental health professional (MHP) experienced in transgender care diagnose GD to ensure that it is not mistaken for a psychiatric condition manifesting as altered gender identity. However, if no one with such experience is available or accessible in the region, it is reasonable for a primary care provider to make the diagnosis and consider initiating hormone therapy without a mental health referral,12 as the expected benefits outweigh the risks of nontreatment.13

Whether or not an MHP confirms a diagnosis of GD, it is still up to the treating provider to confirm the patient’s eligibility and readiness for hormone therapy: He or she should meet DSM-5 or ICD-10 criteria for GD, have no psychiatric comorbidity (eg, schizophrenia, body dysmorphic disorder, or uncontrolled bipolar disorder) likely to interfere with treatment, understand the expected outcomes and the social benefits and risks, and have indicated a willingness to take the hormones responsibly.

Historically, patients were required to have a documented real-life experience, defined as having fully adopted the new gender role in everyday life for at least three months.10,11 This model has fallen out of favor, however, as it is unsupported by evidence and may place transgender individuals at physical and emotional risk. Instead, readiness is confirmed by obtaining informed consent.12

Puberty may be suppressed with a gonadotropin-releasing hormone (GnRH) agonist in adolescents who have a GD diagnosis and are at Tanner stage 2 to 3 of puberty until age 16. At that point, hormone therapy consistent with their gender identification may be initiated (see “How to Help Transgender Teens”).11

 

 

 

Beginning the transition

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

For patients interested in medical interventions, possible therapies include cross-sex hormone administration and gender-affirming surgery. Both are aimed at making the physical and the psychologic more congruent. Hormone treatment (see Table 2) is often essential to reduce the distress of individuals with GD and to help them feel comfortable in their own body.10,11,21 Psychologic conditions, such as depression, tend to improve as the transitioning process gets underway.22

FEMALE-TO-MALE TRANSITION

CASE 1 Jennie R, a 55-year-old postmenopausal patient, comes to your office for an annual exam. Although you’ve been her primary care provider for several years, she confides for the first time that she has never been comfortable as a woman. “I’ve always felt that my body didn’t belong to me,” the patient admits, and goes on to say that for the past several years she has been living as a man. Jennie R says she is ready to start hormone therapy to assist with the gender transition and asks about the process, the benefits and risks, and how quickly she can expect to achieve the desired results.

If Jennie R were your patient, how would you respond?

Masculinizing hormone treatment

As you would explain to a patient like Jennie R, the goal of hormone therapy is to suppress the effects of the sex assigned at birth and replace them with those of the desired gender. In the case of a female transitioning to a male (known as a transman), masculinizing hormones would promote growth of facial and body hair, cessation of menses, increased muscle mass, deepening of the voice, and clitoral enlargement.11,23,24

Physical changes induced by masculinizing hormone therapy have an expected onset of one to six months and achieve maximum effect in approximately two to five years.10,11 Although there have been no controlled clinical trials evaluating the safety or efficacy of any transitional hormone regimen, WPATH and the Center of Excellence for Transgender Health at the University of California, San Francisco, suggest initiating intramuscular or transdermal testosterone at increasing doses until normal physiologic male testosterone levels between 350 and 700 ng/dL are achieved, or until cessation of menses.13,25-28 The dose at which either, or both, occur should be continued as long-term maintenance therapy. Medroxyprogesterone can be added, if necessary for menstrual cessation, and a GnRH agonist or endometrial ablation can be used for refractory uterine bleeding.29,30

Testosterone is not a contraceptive. It is important to emphasize to transmen like Jennie that they remain at risk for pregnancy if they are having sex with fertile males. Caution patients not to assume that the possibility of pregnancy ends when menses stop.

Treat minor adverse effects. Adverse effects of masculinizing hormones include vaginal atrophy, fat redistribution and weight gain, polycythemia, acne, scalp hair loss, sleep apnea, elevated liver enzymes, hyperlipidemia, cardiovascular disease, diabetes, and bone density loss. Increased risk for cancer of the female organs has not been proven.10,11 It is reasonable to treat minor adverse effects after reviewing the risks/benefits of doing so, as discontinuing hormone therapy could be detrimental to the well-being of transitioning patients.11

There are absolute contraindications to masculinizing hormone therapy, however, including pregnancy, unstable coronary artery disease, and untreated polycythemia with a hematocrit > 55%.10

Monitoring is essential. Patients receiving masculinizing hormone therapy should be monitored every three months during the first year and once or twice a year there­after, with a focused history (including mood symptoms), physical exam (including weight and blood pressure), and labs (including complete blood count, liver function, renal function, and lipids) at each visit.11,23 Some clinicians also check estradiol levels until they fall below 50 pg/mL,23,27 while others take the cessation of uterine bleeding for > 6 months as an indicator of estrogen ­suppression.

Preventive health measures continue. Routine screening should continue, based on the patient’s assigned sex at birth. Thus, a transman who has not had a hysterectomy still needs Pap smears, mammograms if the patient has not had a double mastectomy, and bone mineral density (BMD) testing to screen for osteoporosis.31,32 Some experts recommend starting to test BMD at age 50 for patients receiving masculinizing hormones, given the unknown effect of testosterone on bone density.11,31,32

CASE 1 The first question for a transgender patient is about his or her current gender identity, but Jennie R has already reported living as a man. So you start by asking “What name do you prefer to use?” and “Do you prefer to be referred to with male or female pronouns?”

 

 

 

The patient tells you that he sees himself as a man, he wants to be called Jeff, and he prefers male pronouns. You explain that you believe he has gender dysphoria and would benefit from hormone therapy, but it is important to confirm this diagnosis with an MHP. You explain that testosterone can be prescribed for masculinizing effects, and describe the expected effects—more facial and body hair, a deeper voice, and greater muscle mass, among others—and review the likely time frame.

You also discuss the risks of masculinizing hormones (hyperlipidemia, cardiovascular disease, diabetes, and loss of bone density) that will need to be monitored. Before he leaves, you give him the name of an MHP who is experienced in transgender care and tell him to make a follow-up appointment with you after he has seen her. At the conclusion of the visit, you make a note of the patient’s name and gender identity in the chart and inform the staff of the changes.

MALE-TO-FEMALE TRANSITION

CASE 2 Before heading into your office to talk to a new patient named Carl S, you glance at his chart and see that he is a healthy 21-year-old who has come in for a routine physical. When you enter the room, you find Carl wearing a dress, heels, and make-up. After confirming that you have the right patient, you ask, “What is your current gender identity?” “Female,” says Carl, who indicates that she now goes by Carol. The patient has no medical problems, surgical history, or significant family history but reports that she has been taking spironolactone and estrogen for the past three years. Carol also says she has a new female partner and is having unprotected sexual activity.

Feminizing hormone treatment

The desired effects of feminizing hormones include voice change, decreased hair growth, breast growth, body fat redistribution, decreased muscle mass, skin softening, decreased oiliness of skin and hair, and a decrease in spontaneous erections, testicular volume, and sperm production.10,11 The onset of feminizing effects ranges from one month to one year and the expected maximum effect occurs anywhere between three months and five years.10,11 Regimens usually include anti-androgen agents and estrogen.13,26-28

The medications that have been most studied with anti-androgenic effects include spironolactone and 5-α reductase inhibitors (5-ARIs) such as finasteride. Spironolactone inhibits testosterone secretion and inhibits androgen binding to androgen receptors; 5-ARIs block the conversion of testosterone to 5-α-dihydrotestosterone, the more active form.

Estrogen can be administered via oral, sublingual, transdermal, or intramuscular route, but parenteral formulations are preferred to avoid first-pass metabolism. The serum estradiol target is similar to the mean daily level of premenopausal women (< 200 pg/mL) and the level of testosterone should be in the normal female range (< 55 ng/dL).13,26-28

The selection of medications should be individualized for each patient. Comorbidities must be considered, as well as the risk for adverse effects, which include venous thromboembolism, elevated liver enzymes, breast cancer, cardiovascular disease, diabetes, hyperprolactinemia, weight gain, gallstones, cerebrovascular disease, and severe migraine headaches.10,11 Estrogen therapy is not reported to induce hypertrophy or premalignant changes in the prostate.33 As is the case for masculinizing hormones, feminizing hormone therapy should be continued indefinitely for long-term effects.

Frequent monitoring is recommended. Patients taking feminizing hormones (transwomen) should be seen every two to three months in the first year and monitored once or twice a year thereafter. Serum testosterone and estradiol levels should initially be monitored every three months; serum electrolytes, specifically potassium, should be monitored every two to three months in the first year until stable.

 

 

 

CASE 2 You recommend that Carol S be screened annually for sexually transmitted diseases, as you would for any 21-year-old patient. You point out, too, that while estrogen and androgen-suppressing therapy decrease sperm production, there is a possibility that the patient could impregnate a female partner and recommend that contraception be used if the couple is not trying to conceive.

You also discuss the risks and benefits of hormone therapy and reasonable expectations of continued treatment. You ask Carol to schedule a follow-up visit in six months, as her hormone regimen is stable. Finally, if the patient remains on hormone therapy, you mention that the only screening unique to men transitioning to women is for breast cancer, which should begin at age 40 to 50 (as it should for all women).

Gender-affirming surgical options

Surgical management of transgender patients is not within the scope of family medicine. But it is essential to know what procedures are available, as you may have occasion to advocate for patients during the surgical referral process and possibly to provide postoperative care.

For transmen, surgical options include chest reconstruction, hysterectomy/oophorectomy, metoidioplasty (using the clitoris to surgically approximate a penis), phalloplasty, scrotoplasty, urethroplasty, and vaginectomy.10,34 The surgeries available for transwomen are orchiectomy, vaginoplasty, penectomy, breast augmentation, thyroid chondroplasty and voice surgery, and facial feminization.10,34 Keep in mind that not all transgender individuals desire surgery as part of the transitioning process.
 

The authors would like to acknowledge the assistance of Michelle Forcier, MD, MPH, and Karen S. Bernstein, MD, MPH, in the preparation of this manuscript.

 

Civil rights for the lesbian, gay, bisexual, and transgender population have advanced markedly in the past decade, and the medical community has gradually begun to address more of their health concerns. More recently, media attention to transgender individuals has encouraged many more to openly seek care.1,2

It is estimated that anywhere from 0.3% to 5% of the US population identifies as transgender.1-3 While awareness of this population has slowly increased, there is a paucity of research on the hormone treatment that is often essential to patients’ well-being. Studies of surgical options for transgender patients have been minimal, as well.

Primary care providers are uniquely positioned to coordinate medical services and ensure continuity of care for transgender patients as they strive to become their authentic selves. Our goal in writing this article is to equip you with the tools to provide this patient population with sensitive, high-quality care (see Table 1).4-7 Our focus is on the diagnosis of gender dysphoria (GD) and its medical and hormonal management—the realm of primary care providers. We briefly discuss surgical management of GD, as well.

UNDERSTANDING AND DIAGNOSING GENDER DYSPHORIA

Two classification systems are used for diagnoses related to GD: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed (DSM-5)8 and the International Classification of Diseases, 10th Rev (ICD-10).9

ICD-10 criteria use the term gender identity disorder; DSM-5 refers to gender dysphoria instead. It is important to emphasize that these classification systems represent an attempt to categorize a group of signs and symptoms that lead to distress for the patient and are not meant to suggest that being transgender is pathological. In fact, in DSM-5—released in 2013—the American Psychiatric Association revised the terminology to emphasize that such individuals are not “disordered” by the nature of their identity, but rather by the distress that being transgender causes.8

For a diagnosis of GD in children, DSM-5 criteria include characteristics perceived to be incongruent between the child’s sex at birth and the self-identified gender based on preferred activities or dislike of his or her own sexual anatomy. The child must meet six or more of the following for at least six months

  • A repeatedly stated desire to be, or insistence that he or she is, of the other gender
  • In boys, a preference for cross-dressing or simulating female attire; in girls, insistence on wearing only stereotypical masculine clothing
  • Strong and persistent preferences for cross-gender roles in make-believe play or fantasy
  • A strong rejection of toys/games typically associated with the child’s sex
  • Intense desire to participate in stereotypical games and pastimes of the other gender
  • Strong preference for playmates of the other gender
  • A strong dislike of one’s sexual anatomy
  • A strong desire for the primary (eg, penis or vagina) or secondary (eg, menstruation) sex characteristics of the other gender.8

Adolescents and adults must meet two or more of the following for at least six months

  • A noticeable incongruence between the gender that the patient sees themselves as and their sex characteristics
  • An intense need to do away with (or prevent) his or her primary or secondary sex features
  • An intense desire to have the primary and/or secondary sex features of the other gender
  • A deep desire to transform into another gender
  • A profound need for society to treat them as someone of the other gender
  • A powerful assurance of having the characteristic feelings and responses of the other gender.8

For children as well as adolescents and adults, the condition should cause the patient significant distress or significantly affect him or her socially, at work or school, and in other important areas of life.8

 

 

 

Is the patient a candidate for hormone therapy?

Two primary sources—Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7, issued by the World Professional Association for Transgender Health (WPATH)10 and Endocrine Treatment of Transsexual Persons11 by the Endocrine Society—offer clinical practice guidance based on evidence and expert opinion.

WPATH recommends that a mental health professional (MHP) experienced in transgender care diagnose GD to ensure that it is not mistaken for a psychiatric condition manifesting as altered gender identity. However, if no one with such experience is available or accessible in the region, it is reasonable for a primary care provider to make the diagnosis and consider initiating hormone therapy without a mental health referral,12 as the expected benefits outweigh the risks of nontreatment.13

Whether or not an MHP confirms a diagnosis of GD, it is still up to the treating provider to confirm the patient’s eligibility and readiness for hormone therapy: He or she should meet DSM-5 or ICD-10 criteria for GD, have no psychiatric comorbidity (eg, schizophrenia, body dysmorphic disorder, or uncontrolled bipolar disorder) likely to interfere with treatment, understand the expected outcomes and the social benefits and risks, and have indicated a willingness to take the hormones responsibly.

Historically, patients were required to have a documented real-life experience, defined as having fully adopted the new gender role in everyday life for at least three months.10,11 This model has fallen out of favor, however, as it is unsupported by evidence and may place transgender individuals at physical and emotional risk. Instead, readiness is confirmed by obtaining informed consent.12

Puberty may be suppressed with a gonadotropin-releasing hormone (GnRH) agonist in adolescents who have a GD diagnosis and are at Tanner stage 2 to 3 of puberty until age 16. At that point, hormone therapy consistent with their gender identification may be initiated (see “How to Help Transgender Teens”).11

 

 

 

Beginning the transition

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

For patients interested in medical interventions, possible therapies include cross-sex hormone administration and gender-affirming surgery. Both are aimed at making the physical and the psychologic more congruent. Hormone treatment (see Table 2) is often essential to reduce the distress of individuals with GD and to help them feel comfortable in their own body.10,11,21 Psychologic conditions, such as depression, tend to improve as the transitioning process gets underway.22

FEMALE-TO-MALE TRANSITION

CASE 1 Jennie R, a 55-year-old postmenopausal patient, comes to your office for an annual exam. Although you’ve been her primary care provider for several years, she confides for the first time that she has never been comfortable as a woman. “I’ve always felt that my body didn’t belong to me,” the patient admits, and goes on to say that for the past several years she has been living as a man. Jennie R says she is ready to start hormone therapy to assist with the gender transition and asks about the process, the benefits and risks, and how quickly she can expect to achieve the desired results.

If Jennie R were your patient, how would you respond?

Masculinizing hormone treatment

As you would explain to a patient like Jennie R, the goal of hormone therapy is to suppress the effects of the sex assigned at birth and replace them with those of the desired gender. In the case of a female transitioning to a male (known as a transman), masculinizing hormones would promote growth of facial and body hair, cessation of menses, increased muscle mass, deepening of the voice, and clitoral enlargement.11,23,24

Physical changes induced by masculinizing hormone therapy have an expected onset of one to six months and achieve maximum effect in approximately two to five years.10,11 Although there have been no controlled clinical trials evaluating the safety or efficacy of any transitional hormone regimen, WPATH and the Center of Excellence for Transgender Health at the University of California, San Francisco, suggest initiating intramuscular or transdermal testosterone at increasing doses until normal physiologic male testosterone levels between 350 and 700 ng/dL are achieved, or until cessation of menses.13,25-28 The dose at which either, or both, occur should be continued as long-term maintenance therapy. Medroxyprogesterone can be added, if necessary for menstrual cessation, and a GnRH agonist or endometrial ablation can be used for refractory uterine bleeding.29,30

Testosterone is not a contraceptive. It is important to emphasize to transmen like Jennie that they remain at risk for pregnancy if they are having sex with fertile males. Caution patients not to assume that the possibility of pregnancy ends when menses stop.

Treat minor adverse effects. Adverse effects of masculinizing hormones include vaginal atrophy, fat redistribution and weight gain, polycythemia, acne, scalp hair loss, sleep apnea, elevated liver enzymes, hyperlipidemia, cardiovascular disease, diabetes, and bone density loss. Increased risk for cancer of the female organs has not been proven.10,11 It is reasonable to treat minor adverse effects after reviewing the risks/benefits of doing so, as discontinuing hormone therapy could be detrimental to the well-being of transitioning patients.11

There are absolute contraindications to masculinizing hormone therapy, however, including pregnancy, unstable coronary artery disease, and untreated polycythemia with a hematocrit > 55%.10

Monitoring is essential. Patients receiving masculinizing hormone therapy should be monitored every three months during the first year and once or twice a year there­after, with a focused history (including mood symptoms), physical exam (including weight and blood pressure), and labs (including complete blood count, liver function, renal function, and lipids) at each visit.11,23 Some clinicians also check estradiol levels until they fall below 50 pg/mL,23,27 while others take the cessation of uterine bleeding for > 6 months as an indicator of estrogen ­suppression.

Preventive health measures continue. Routine screening should continue, based on the patient’s assigned sex at birth. Thus, a transman who has not had a hysterectomy still needs Pap smears, mammograms if the patient has not had a double mastectomy, and bone mineral density (BMD) testing to screen for osteoporosis.31,32 Some experts recommend starting to test BMD at age 50 for patients receiving masculinizing hormones, given the unknown effect of testosterone on bone density.11,31,32

CASE 1 The first question for a transgender patient is about his or her current gender identity, but Jennie R has already reported living as a man. So you start by asking “What name do you prefer to use?” and “Do you prefer to be referred to with male or female pronouns?”

 

 

 

The patient tells you that he sees himself as a man, he wants to be called Jeff, and he prefers male pronouns. You explain that you believe he has gender dysphoria and would benefit from hormone therapy, but it is important to confirm this diagnosis with an MHP. You explain that testosterone can be prescribed for masculinizing effects, and describe the expected effects—more facial and body hair, a deeper voice, and greater muscle mass, among others—and review the likely time frame.

You also discuss the risks of masculinizing hormones (hyperlipidemia, cardiovascular disease, diabetes, and loss of bone density) that will need to be monitored. Before he leaves, you give him the name of an MHP who is experienced in transgender care and tell him to make a follow-up appointment with you after he has seen her. At the conclusion of the visit, you make a note of the patient’s name and gender identity in the chart and inform the staff of the changes.

MALE-TO-FEMALE TRANSITION

CASE 2 Before heading into your office to talk to a new patient named Carl S, you glance at his chart and see that he is a healthy 21-year-old who has come in for a routine physical. When you enter the room, you find Carl wearing a dress, heels, and make-up. After confirming that you have the right patient, you ask, “What is your current gender identity?” “Female,” says Carl, who indicates that she now goes by Carol. The patient has no medical problems, surgical history, or significant family history but reports that she has been taking spironolactone and estrogen for the past three years. Carol also says she has a new female partner and is having unprotected sexual activity.

Feminizing hormone treatment

The desired effects of feminizing hormones include voice change, decreased hair growth, breast growth, body fat redistribution, decreased muscle mass, skin softening, decreased oiliness of skin and hair, and a decrease in spontaneous erections, testicular volume, and sperm production.10,11 The onset of feminizing effects ranges from one month to one year and the expected maximum effect occurs anywhere between three months and five years.10,11 Regimens usually include anti-androgen agents and estrogen.13,26-28

The medications that have been most studied with anti-androgenic effects include spironolactone and 5-α reductase inhibitors (5-ARIs) such as finasteride. Spironolactone inhibits testosterone secretion and inhibits androgen binding to androgen receptors; 5-ARIs block the conversion of testosterone to 5-α-dihydrotestosterone, the more active form.

Estrogen can be administered via oral, sublingual, transdermal, or intramuscular route, but parenteral formulations are preferred to avoid first-pass metabolism. The serum estradiol target is similar to the mean daily level of premenopausal women (< 200 pg/mL) and the level of testosterone should be in the normal female range (< 55 ng/dL).13,26-28

The selection of medications should be individualized for each patient. Comorbidities must be considered, as well as the risk for adverse effects, which include venous thromboembolism, elevated liver enzymes, breast cancer, cardiovascular disease, diabetes, hyperprolactinemia, weight gain, gallstones, cerebrovascular disease, and severe migraine headaches.10,11 Estrogen therapy is not reported to induce hypertrophy or premalignant changes in the prostate.33 As is the case for masculinizing hormones, feminizing hormone therapy should be continued indefinitely for long-term effects.

Frequent monitoring is recommended. Patients taking feminizing hormones (transwomen) should be seen every two to three months in the first year and monitored once or twice a year thereafter. Serum testosterone and estradiol levels should initially be monitored every three months; serum electrolytes, specifically potassium, should be monitored every two to three months in the first year until stable.

 

 

 

CASE 2 You recommend that Carol S be screened annually for sexually transmitted diseases, as you would for any 21-year-old patient. You point out, too, that while estrogen and androgen-suppressing therapy decrease sperm production, there is a possibility that the patient could impregnate a female partner and recommend that contraception be used if the couple is not trying to conceive.

You also discuss the risks and benefits of hormone therapy and reasonable expectations of continued treatment. You ask Carol to schedule a follow-up visit in six months, as her hormone regimen is stable. Finally, if the patient remains on hormone therapy, you mention that the only screening unique to men transitioning to women is for breast cancer, which should begin at age 40 to 50 (as it should for all women).

Gender-affirming surgical options

Surgical management of transgender patients is not within the scope of family medicine. But it is essential to know what procedures are available, as you may have occasion to advocate for patients during the surgical referral process and possibly to provide postoperative care.

For transmen, surgical options include chest reconstruction, hysterectomy/oophorectomy, metoidioplasty (using the clitoris to surgically approximate a penis), phalloplasty, scrotoplasty, urethroplasty, and vaginectomy.10,34 The surgeries available for transwomen are orchiectomy, vaginoplasty, penectomy, breast augmentation, thyroid chondroplasty and voice surgery, and facial feminization.10,34 Keep in mind that not all transgender individuals desire surgery as part of the transitioning process.
 

The authors would like to acknowledge the assistance of Michelle Forcier, MD, MPH, and Karen S. Bernstein, MD, MPH, in the preparation of this manuscript.

References

 

 

1. Pew Research Center. A survey of LGBT Americans: attitudes, experiences and values in changing times. www.pewsocialtrends.org/2013/06/13/a-survey-of-lgbt-americans. Accessed January 13, 2017.
2. Gates GJ. How many people are lesbian, gay, bisexual and transgender? http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf. Accessed January 13, 2017.
3. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav. 1996;25:589-600.
4. Bhola S. An ally’s guide to terminology: talking about LGBT people & equality. www.glaad.org/2011/07/28/an-allys-guide-to-terminology-talking-about-lgbt-people-equality. Accessed January 13, 2017.
5. University of California, San Francisco. Transgender terminology. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/tcoe?page=protocol-terminology. Accessed January 13, 2017.
6. Istar A. How queer! The development of gender identity and sexual orientation in LGBTQ-headed families. Fam Process. 2010;49:268-290.
7. Goins ES, Pye D. Check the box that best describes you: reflexively managing theory and praxis in LGBTQ health communication research. Health Commun. 2013;28:397-407.
8. American Psychiatric Association. Gender dysphoria. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013: 451-459.
9. World Health Organization.  The International Classification of Diseases, 10th rev. Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992; Geneva.
10. Coleman E, Bockting W, Botzer M, et al; World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgender. 2011; 13:165-232.
11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endo Metabol. 2009;94:3132-3154.
12. University of California, San Francisco. Assessing readiness for hormones. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/tcoe?page=protocol-hormone-ready. Accessed January 13, 2017.
13. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):S31-S36.
14. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20:725-732.
15. Gay, Lesbian, and Straight Education Network (GLSEN). Harsh realities. The experiences of transgender youth in our nation’s schools. www.glsen.org/sites/default/files/Harsh%20Realities.pdf. Accessed January 13, 2017.
16. Berman M, Balingit M. Eleven states sue Obama administration over bathroom guidance for transgender students. May 25, 2016. Washington Post. www.washingtonpost.com/news/post-nation/wp/2016/05/25/texas-governor-says-state-will-sue-obama-administration-over-bathroom-directive/. Accessed January 13, 2017.
17. de Vries AL, Cohen-Kettenis PT, Delemarre-van de Waal H. Clinical management of gender dysphoria in adolescents. 2006. Vancouver Coastal Health - Transgender Health Program. www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf. Accessed January 13, 2017.
18. TransYouth Family Allies. Empowering transgender youth & families. www.imatyfa.org/. Accessed January 13, 2017.
19. Human Rights Campaign. On our own: a survival guide for independent LGBTQ youth. www.hrc.org/resources/on-our-own-a-survival-guide-for-independent-lgbtq-youth. Accessed January 13, 2017.
20. Gay, Lesbian, Bisexual, and Transgender National Help Center. www.glbthotline.org. Accessed January 13, 2017.
21. University of California, San Francisco. Hormone administration. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-hormones. Accessed January 13, 2017.
22. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013;201:996-1000.
23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
24. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20-28.
25. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008; 5:765-776.
26. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59:409-418.
27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-3473.
28. Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12-21.
29. Dickersin K, Munro MG, Clark M, et al. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2007;110:1279-1289.
30. Prasad P, Powell MC. Prospective observational study of Thermablate Endometrial Ablation System as an outpatient procedure. J Minim Invasive Gynecol. 2008;15:476-479.
31. University of California, San Francisco. General prevention and screening. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-screening. Accessed January 13, 2017.
32. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995; 82:341.
33. Meriggiola MC, Gava G. Endocrine care of transpeople part II: a review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83:607-615. 
34. University of California, San Francisco. Surgical options. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-surgery. Accessed January 13, 2017.

References

 

 

1. Pew Research Center. A survey of LGBT Americans: attitudes, experiences and values in changing times. www.pewsocialtrends.org/2013/06/13/a-survey-of-lgbt-americans. Accessed January 13, 2017.
2. Gates GJ. How many people are lesbian, gay, bisexual and transgender? http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf. Accessed January 13, 2017.
3. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav. 1996;25:589-600.
4. Bhola S. An ally’s guide to terminology: talking about LGBT people & equality. www.glaad.org/2011/07/28/an-allys-guide-to-terminology-talking-about-lgbt-people-equality. Accessed January 13, 2017.
5. University of California, San Francisco. Transgender terminology. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/tcoe?page=protocol-terminology. Accessed January 13, 2017.
6. Istar A. How queer! The development of gender identity and sexual orientation in LGBTQ-headed families. Fam Process. 2010;49:268-290.
7. Goins ES, Pye D. Check the box that best describes you: reflexively managing theory and praxis in LGBTQ health communication research. Health Commun. 2013;28:397-407.
8. American Psychiatric Association. Gender dysphoria. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013: 451-459.
9. World Health Organization.  The International Classification of Diseases, 10th rev. Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992; Geneva.
10. Coleman E, Bockting W, Botzer M, et al; World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgender. 2011; 13:165-232.
11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endo Metabol. 2009;94:3132-3154.
12. University of California, San Francisco. Assessing readiness for hormones. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/tcoe?page=protocol-hormone-ready. Accessed January 13, 2017.
13. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):S31-S36.
14. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20:725-732.
15. Gay, Lesbian, and Straight Education Network (GLSEN). Harsh realities. The experiences of transgender youth in our nation’s schools. www.glsen.org/sites/default/files/Harsh%20Realities.pdf. Accessed January 13, 2017.
16. Berman M, Balingit M. Eleven states sue Obama administration over bathroom guidance for transgender students. May 25, 2016. Washington Post. www.washingtonpost.com/news/post-nation/wp/2016/05/25/texas-governor-says-state-will-sue-obama-administration-over-bathroom-directive/. Accessed January 13, 2017.
17. de Vries AL, Cohen-Kettenis PT, Delemarre-van de Waal H. Clinical management of gender dysphoria in adolescents. 2006. Vancouver Coastal Health - Transgender Health Program. www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf. Accessed January 13, 2017.
18. TransYouth Family Allies. Empowering transgender youth & families. www.imatyfa.org/. Accessed January 13, 2017.
19. Human Rights Campaign. On our own: a survival guide for independent LGBTQ youth. www.hrc.org/resources/on-our-own-a-survival-guide-for-independent-lgbtq-youth. Accessed January 13, 2017.
20. Gay, Lesbian, Bisexual, and Transgender National Help Center. www.glbthotline.org. Accessed January 13, 2017.
21. University of California, San Francisco. Hormone administration. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-hormones. Accessed January 13, 2017.
22. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013;201:996-1000.
23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
24. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20-28.
25. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008; 5:765-776.
26. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59:409-418.
27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-3473.
28. Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12-21.
29. Dickersin K, Munro MG, Clark M, et al. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2007;110:1279-1289.
30. Prasad P, Powell MC. Prospective observational study of Thermablate Endometrial Ablation System as an outpatient procedure. J Minim Invasive Gynecol. 2008;15:476-479.
31. University of California, San Francisco. General prevention and screening. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-screening. Accessed January 13, 2017.
32. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995; 82:341.
33. Meriggiola MC, Gava G. Endocrine care of transpeople part II: a review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83:607-615. 
34. University of California, San Francisco. Surgical options. UCSF Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=protocol-surgery. Accessed January 13, 2017.

Issue
Clinician Reviews - 27(2)
Issue
Clinician Reviews - 27(2)
Page Number
28-32,40-41,52
Page Number
28-32,40-41,52
Publications
Publications
Topics
Article Type
Display Headline
Transgender Patients: Providing Sensitive Care
Display Headline
Transgender Patients: Providing Sensitive Care
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media

Transgender patients: Providing sensitive care

Article Type
Changed
Thu, 03/28/2019 - 15:06
Display Headline
Transgender patients: Providing sensitive care
PRACTICE RECOMMENDATIONS

› Refer transgender patients to a mental health provider with experience in treating this patient population for diagnosis of gender dysphoria. B
› Confirm patients’ eligibility for hormone therapy and obtain informed consent before initiating it. B
› Treat minor adverse effects of hormone therapy whenever possible, as discontinuing the hormones may be detrimental to the well-being of patients in the process of transitioning. B
› Continue recommended screenings based on the sex the patient was assigned at birth, unless the organ or tissue in question has been surgically removed. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

 

Civil rights for the lesbian, gay, bisexual, and transgender population have advanced markedly in the past decade, and the medical community has gradually begun to address more of their health concerns. More recently, media attention to transgender individuals—although focused primarily on the “appropriate” use of restrooms—has encouraged many more to openly seek care.1,2

It is estimated that anywhere from 0.3% to 5% of the US population identifies as transgender.1-3 While awareness of this population has slowly increased, there is a paucity of research on the hormone treatment that is often essential to patients’ well-being. Studies of surgical options for transgender patients have been minimal, as well.

Family physicians are uniquely positioned to coordinate medical services and ensure continuity of care for transgender patients as they strive to become their authentic selves. Our goal in writing this article is to equip you with the tools to provide this patient population with sensitive, high-quality care (TABLE 1).4-7 Our focus is on the diagnosis of gender dysphoria (GD) and its medical and hormonal management—the realm of primary care providers. We briefly discuss surgical management of GD, as well.

 

 

Understanding and diagnosing gender dysphoria

Two classification systems are used for diagnoses related to GD: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed. (DSM-5)8 and the International Classification of Diseases, 10th Rev. (ICD-10).9

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

ICD-10 criteria use the term “gender identity disorder;” DSM-5 refers to “gender dysphoria” instead. It is important to emphasize that these classification systems represent an attempt to categorize a group of signs and symptoms that lead to distress for the patient, and are not meant to suggest that being transgender is pathological. In fact, in DSM-5—released in 2013—the American Psychiatric Association revised the terminology to emphasize that such individuals are not “disordered” by the nature of their identity, but rather by the distress that being transgender causes.8

For a diagnosis of GD in children, DSM-5 criteria include characteristics perceived to be incongruent between the child’s sex at birth and the self-identified gender based on preferred activities or dislike of his or her own sexual anatomy. The child must meet 6 or more of the following for at least 6 months:

  • a repeatedly stated desire to be, or insistence that he or she is, of the other gender
  • in boys, a preference for cross-dressing or simulating female attire; in girls, insistence on wearing only stereotypical masculine clothing
  • strong and persistent preferences for cross-gender roles in make-believe play or fantasy
  • a strong rejection of toys/games typically associated with the child’s sex
  • intense desire to participate in stereotypical games and pastimes of the other gender
  • strong preference for playmates of the other gender
  • a strong dislike of one’s sexual anatomy
  • a strong desire for the primary (eg, penis or vagina) or secondary (eg, menstruation) sex characteristics of the other gender.8

Adolescents and adults must meet 2 or more of the following for at least 6 months:

  • a noticeable incongruence between the gender that the patient sees themselves as and their sex characteristics
  • an intense need to do away with (or prevent) his or her primary or secondary sex features
  • an intense desire to have the primary and/or secondary sex features of the other gender
  • a deep desire to transform into another gender
  • a profound need for society to treat them as someone of the other gender
  • a powerful assurance of having the characteristic feelings and responses of the other gender.8

For children as well as adolescents and adults, the condition should cause the patient significant distress or significantly affect him or her socially, at work or school, and in other important areas of life.8

Is the patient a candidate for hormone therapy?

Two primary sources—Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7, issued by the World Professional Association for Transgender Health (WPATH)10 and Endocrine Treatment of Transsexual Persons11 by the Endocrine Society—offer clinical practice guidance based on evidence and expert opinion.

WPATH recommends that a mental health professional (MHP) experienced in transgender care diagnose GD to ensure that it is not mistaken for a psychiatric condition manifesting as altered gender identity. However, if no one with such experience is available or accessible in the region, it is reasonable for a primary care physician to make the diagnosis and consider initiating hormone therapy without a mental health referral,12 as the expected benefits outweigh the risks of nontreatment.13

Whether or not a MHP confirms a diagnosis of GD, it is still up to the treating physician to confirm the patient’s eligibility and readiness for hormone therapy: He or she should meet DSM-5 or ICD-10 criteria for GD, have no psychiatric comorbidity (eg, schizophrenia, body dysmorphic disorder, or uncontrolled bipolar disorder) likely to interfere with treatment, understand the expected outcomes and the social benefits and risks, and have indicated a willingness to take the hormones responsibly.

Historically, patients were required to have a documented Real-Life Experience (RLE), defined as having fully adopted the new gender role in everyday life for at least 3 months.10,11 This model has fallen out of favor, however, as it is unsupported by evidence and may place transgender individuals at physical and emotional risk.. Instead, readiness is confirmed by obtaining informed consent.12

Puberty may be suppressed with a gonadotropin-releasing hormone (GnRH) agonist in adolescents who have a GD diagnosis and are at Tanner stage 2 to 3 of puberty until age 16. At that point, hormone therapy consistent with their gender identification may be initiated.11 (See “How to help transgender teens.”11,14-20)

 

 

SIDEBAR
How to help transgender teens

Gender exploration is a normal part of childhood. Changes that occur during puberty cause many adolescents to question their ideas of gender and sexuality, but those with persistent gender nonconformity or extreme body dysphoria should receive medical and mental health care as early as possible.

A mental health professional (MHP) can help families create a safe, unconditionally accepting, and supportive environment in which their child can develop into his or her authentic self. A specialist in adolescent gender dysphoria (GD) should be consulted before initiating hormone therapy. Family physicians are well positioned to provide follow-up and ongoing care.

Initiating hormone suppression for adolescents with GD early in puberty can greatly reduce the emotional trauma, as well as the need for surgery related to unwanted secondary sex characteristics. Hormone suppression also gives adolescents more time to explore their gender nonconformity and developmental needs. Treatment with a gonadotropin-releasing hormone agonist such as leuprolide or histrelin can be initiated for adolescents in Tanner Stage 2, assessed by hormone levels, as well as breast, testicle, and pubic hair development (childgrowthfoundation.org/CMS/FILES/Puberty_and_the_Tanner_Stages.pdf), to suppress ongoing puberty.11,14

The effects of puberty blockers are reversible. If preferred, however, medication management can allow teens to progress directly from hormone suppression to the puberty of their self-identified gender once initiation of adult transgender hormone therapy is started—typically around the age of 16.11

Some adolescents may seek medical care well after puberty has begun. It is possible to use hormone suppression therapy after a teen has started to develop unwanted secondary sex characteristics. However, such patients may get less benefit from puberty blockers and often derive more benefit from initiation of cross-gender hormones.

Safety—a broader perspective. Regardless of medical treatment or the age at which treatment is begun, parents and patients need to be reminded that gender transition is about more than hormones. It is crucial that either the MHP or primary care physician, or both, address safety issues and work with the transgender individual to create a comprehensive plan for his or her health, safety, and social well-being.

Psychosocial concerns for transgender youth are vast, often encompassing rejection by peers and potentially, by family and authority figures; harassment; physical, emotional, and sexual abuse; inadequate housing; legal problems; lack of financial support; and educational difficulties.15 School is a particular source of concern. A survey by the Gay, Lesbian and Straight Education Network found, for instance, that nearly 9 in 10 transgender youth had been verbally harassed at school because of their gender expression. More than half also reported being physically harassed (eg, pushed or shoved).15

Bathroom use in schools is a major issue, as well, with transgender youth often prevented from using the restroom or locker room that coincides with their gender identity. In May, 11 states filed a lawsuit against the Obama administration for directing schools to allow such students to do so or risk the loss of federal funds.16

Tools and support. In 2006, the Vancouver Coastal Health, Transcend Transgender Support & Education Society, and the Canadian Rainbow Health Coalition published guidelines for the care of transgender adolescents, including a modification of the HEEADSSS tool (used to assess teens’ psychosocial well-being) specific to transgender youth.17 (See http://www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf.) The tool can help you identify possible areas of concern and intervene, as needed.

If a patient reports feeling especially vulnerable at school, for example, encourage him or her to identify supportive friends, family members, teachers, or school counselors who can help create safe networks. Suggest that a teen who feels threatened travel in groups whenever possible. Stress to family members that their acceptance is key to nurturing positive feelings in youth with GD. And refer patients and parents to organizations that provide information and support.

Chief among them are Trans Youth Family Allies18 (www.imatyfa.org), which provides resources for parents, educators, and health care practitioners; the Human Rights Campaign, which has created a survival guide for gay and transgender youth who are forced to seek independent living19 (available at hrc-assets.s3-website-us-east-1.amazonaws.com//files/assets/resources/HRC-OnOurOwn-LGBTQYouth.pdf), and the Gay, Lesbian, Bisexual, and Transgender National Help Center, which hosts a GLBT national hotline (888-843-4564) and a weekly Trans Teen Online Talk Group.20 For more information about the online talk group, go to glbthotline.org and click on “transteens.”

 

 

Beginning the transition

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

For patients interested in medical interventions, possible therapies include cross-sex hormone administration and gender-affirming surgery. Both are aimed at making the physical and the psychological more congruent. Hormone treatment (TABLE 2)10,11,21 is often essential to reduce the distress of individuals with GD and to help them feel comfortable in their own body. Psychological conditions, such as depression, tend to improve as the transitioning process gets underway.22

 

 

 

Female-to-male transition

CASE 1

Jennie R, a 55-year-old postmenopausal patient, comes to your office for an annual exam. Although you’ve been her primary care physician for several years, she confides for the first time that she has never been comfortable as a woman. “I’ve always felt that my body didn’t belong to me,” the patient admits, and goes on to say that for the last several years she has been living as a man. Jennie R says she is ready to start hormone therapy to assist with the gender transition and asks about the process, the benefits and risks, and how quickly she can expect to achieve the desired results.

If Jennie R were your patient, how would you respond?

Masculinizing hormone treatment

As you would explain to a patient like Jennie R, the goal of hormone therapy is to suppress the effects of the sex assigned at birth and replace them with those of the desired gender. In the case of a female transitioning to a male (known as a transman), masculinizing hormones would promote growth of facial and body hair, cessation of menses, increased muscle mass, deepening of the voice, and clitoral enlargement.11,23,24

Physical changes induced by masculinizing hormone therapy have an expected onset of one to 6 months and achieve maximum effect in approximately 2 to 5 years.10,11 Although there have been no controlled clinical trials evaluating the safety or efficacy of any transitional hormone regimen, WPATH and the Center of Excellence for Transgender Health at the University of California, San Francisco, suggest initiating intramuscular or transdermal testosterone at increasing doses until normal physiologic male testosterone levels between 350 and 700 ng/dL are achieved, or until cessation of menses.13,25-28 The dose at which either, or both, occur should be continued as long-term maintenance therapy. Medroxyprogesterone can be added, if necessary for menstrual cessation, and a GnRH agonist or endometrial ablation can be used for refractory uterine bleeding.29,30

Psychological conditions such as depression tend to improve when a transgender individual begins the transitioning process.

Testosterone is not a contraceptive. It is important to emphasize to transmen like Jennie that they remain at risk of pregnancy if they are having sex with fertile males. Caution patients not to assume that the possibility of pregnancy ends when menses stop.

Treat minor adverse effects. Adverse effects of masculinizing hormones include vaginal atrophy, fat redistribution and weight gain, polycythemia, acne, scalp hair loss, sleep apnea, elevated liver enzymes, hyperlipidemia, cardiovascular disease, diabetes, and bone density loss. Increased risk of cancer of the female organs has not been proven.10,11 It is reasonable to treat minor adverse effects after reviewing the risks vs benefits of doing so, as discontinuing hormone therapy could be detrimental to the well-being of transitioning patients.11

There are absolute contraindications to masculinizing hormone therapy, however, including pregnancy, unstable coronary artery disease, and untreated polycythemia with a hematocrit >55%.10

Monitoring is essential. Patients receiving masculinizing hormone therapy should be monitored every 3 months during the first year and once or twice a year thereafter, with a focused history (including mood symptoms), physical exam (including weight and blood pressure), and labs (including complete blood count, liver function, renal function, and lipids) at each visit.11,23 Some clinicians also check estradiol levels until they fall below 50 pg/mL,23,27 while others take the cessation of uterine bleeding for >6 months as an indicator of estrogen suppression.

Remind patients of the need for contraception, pointing out that a male transitioning to a female may still impregnate a female partner and a female transitioning to a male may still conceive.

Preventive health measures continue. Routine screening should continue, based on the patient’s assigned sex at birth. Thus, a transman who has not had a hysterectomy still needs Pap smears, mammograms if the patient has not had a double mastectomy, and bone mineral density (BMD) testing to screen for osteoporosis.31,32 Some experts recommend starting to test BMD at age 50 for patients receiving masculinizing hormones, given the unknown effect of testosterone on bone density.11,31,32

CASE 1

The first question for a transgender patient is about his or her current gender identity, but Jennie R has already reported living as a man. So you start by asking “What name do you prefer to use?” and “Do you prefer to be referred to with male or female pronouns?”

The patient tells you that he sees himself as a man, he wants to be called Jeff, and he prefers male pronouns. You explain that you believe he has gender dysphoria and would benefit from hormone therapy, but it is important to confirm this diagnosis with a MHP. You explain that testosterone can be prescribed for masculinizing effects, and describe the expected effects—more facial and body hair, a deeper voice and greater muscle mass, among others—and review the likely time frame

You also discuss the risks of masculinizing hormones (hyperlipidemia, cardiovascular disease, diabetes, and loss of bone density) that will need to be monitored. Before he leaves, you give him the name of a MHP who is experienced in transgender care and tell him to make a follow-up appointment with you after he has seen her. At the conclusion of the visit, you make a note of the patient’s name and gender identity in the chart and inform the staff of the changes.

 

 

Male-to-female transition

CASE 2

Before heading into your office to talk to a new patient named Carl S, you glance at his chart and see that he is a healthy 21-year-old who has come in for a routine physical. When you enter the room, you find Carl wearing a dress, heels, and make-up. After confirming that you have the right patient, you ask, “What is your current gender identity?” “Female,” says Carl, who indicates that she now goes by Carol. The patient has no medical problems, surgical history, or significant family history, but reports that she has been taking spironolactone and estrogen for the past 3 years. Carol also says she has a new female partner and is having unprotected sexual activity.

Feminizing hormone treatment

The desired effects of feminizing hormones include voice change, decreased hair growth, breast growth, body fat redistribution, decreased muscle mass, skin softening, decreased oiliness of skin and hair, and a decrease in spontaneous erections, testicular volume, and sperm production.10,11 The onset of feminizing effects ranges from one month to one year and the expected maximum effect occurs anywhere between 3 months and 5 years.10,11 Regimens usually include anti-androgen agents and estrogen.13,26-28

The medications that have been most studied with anti-androgenic effects include spironolactone and 5-alpha reductase inhibitors (5-ARIs) such as finasteride. Spironolactone inhibits testosterone secretion and inhibits androgen binding to androgen receptors; 5-ARIs block the conversion of testosterone to 5-alpha-dihydrotestosterone, the more active form.

Males transitioning to females should undergo breast cancer screening beginning at 40 to 50 years of age if they remain on hormone therapy.

Estrogen can be administered via oral, sublingual, transdermal, or intramuscular route, but parenteral formulations are preferred to avoid first-pass metabolism. The serum estradiol target is similar to the mean daily level of premenopausal women (<200 pg/mL) and the level of testosterone should be in the normal female range (<55 ng/dL).13,26-28

The selection of medications should be individualized for each patient. Comorbidities must be considered, as well as the risk of adverse effects, which include venous thromboembolism, elevated liver enzymes, breast cancer, cardiovascular disease, diabetes, hyperprolactinemia, weight gain, gallstones, cerebrovascular disease, and severe migraine headaches.10,11 Estrogen therapy is not reported to induce hypertrophy or premalignant changes in the prostate.33 As is the case for masculinizing hormones, feminizing hormone therapy should be continued indefinitely for long-term effects.

Frequent monitoring is recommended. Patients on feminizing hormones (transwomen) should be seen every 2 to 3 months in the first year and monitored once or twice a year thereafter. Serum testosterone and estradiol levels should initially be monitored every 3 months; serum electrolytes, specifically potassium, should be monitored every 2 to 3 months in the first year until stable.

CASE 2

You recommend that Carol S be screened annually for sexually transmitted diseases, as you would for any 21-year-old patient. You point out, too, that while estrogen and androgen-suppressing therapy decrease sperm production, there is a possibility that the patient could impregnate a female partner and recommend that contraception be used if the couple is not trying to conceive.

You also discuss the risks and benefits of hormone therapy and reasonable expectations of continued treatment. You ask Carol to schedule a follow-up visit in 6 months, as her hormone regimen is stable. Finally, if the patient remains on hormone therapy, you mention that the only screening unique to men transitioning to women is for breast cancer, which should begin at 40 to 50 years of age (as it is for all women).

Gender-affirming surgical options

Nearly 9 in 10 transgender youth report being verbally harassed at school because of their gender expression. More than half report being physically harassed.

Surgical management of transgender patients is not within the scope of family medicine. But it is essential to know what procedures are available as you may have occasion to advocate for patients during the surgical referral process and possibly to provide postoperative care.

For transmen, surgical options include chest reconstruction, hysterectomy/oophorectomy, metoidioplasty (using the clitoris to surgically approximate a penis), phalloplasty, scrotoplasty, urethroplasty, and vaginectomy.10,34 The surgeries available for transwomen are orchiectomy, vaginoplasty, penectomy, breast augmentation, thyroid chondroplasty and voice surgery, and facial feminization.10,34 Keep in mind that not all transgender individuals desire surgery as part of the transitioning process.

CORRESPONDENCE
Abbas Hyderi, MD, MPH, 1919 West Taylor Street, M/C 663, Chicago, IL 60612; ahyder2@uic.edu.

The authors would like to acknowledge the assistance of Michelle Forcier, MD, MPH, and Karen S. Bernstein, MD, MPH, in the preparation of this manuscript. 

References

1. Pew Research Center. A survey of LGBT Americans: attitudes, experiences and values in changing times. Available at: http://www.pewsocialtrends.org/2013/06/13/a-survey-of-lgbt-americans. Accessed June 24, 2015.

2. Gates GJ. How many people are lesbian, gay, bisexual and transgender? Available at: http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf. Accessed May 25, 2016.

3. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav. 1996;25:589-600.

4. Bhola S. An ally’s guide to terminology: talking about LGBT people & equality. Available at: http://www.glaad.org/2011/07/28/an-allys-guide-to-terminology-talking-about-lgbt-people-equality. Accessed June 24, 2015.

5. University of California, San Francisco. Transgender terminology. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/tcoe?page=protocol-terminology. Accessed June 24, 2015.

6. Istar A. How queer! the development of gender identity and sexual orientation in LGBTQ-headed families. Fam Process. 2010;49:268-290.

7. Goins ES, Pye D. Check the box that best describes you: reflexively managing theory and praxis in LGBTQ health communication research. Health Commun. 2013;28:397-407.

8. American Psychiatric Association. Gender dysphoria. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association. 2013:451-459.

9. World Health Organization. The International Classification of Diseases, 10th rev. Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992; Geneva.

10. Coleman E, Bockting W, Botzer M, et al; World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgender. 2011;13:165–232.

11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine Treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline. J Clin Endo Metabol. 2009;94:3132–3154.

12. University of California, San Francisco. Assessing readiness for hormones. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/tcoe?page=protocol-hormone-ready. Accessed June 24, 2015.

13. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):S31-S614.

14. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20:725-732.

15. Gay, Lesbian, and Straight Education Network (GLSEN). Harsh realities. The experiences of transgender youth in our nation’s schools. Available at: https://www.glsen.org/sites/default/files/Harsh%20Realities.pdf. Accessed May 29, 2016.

16. Berman M, Balingit M. Eleven states sue Obama administration over bathroom guidance for transgender students. May 25, 2016. Washington Post. Available at: https://www.washingtonpost.com/news/post-nation/wp/2016/05/25/texas-governor-says-state-will-sue-obama-administration-over-bathroom-directive/. Accessed May 31, 2016.

17. de Vries AL, Cohen-Kettenis PT, Delemarre-van de Waal H. Clinical management of gender dysphoria in adolescents. 2006. Vancouver Coastal Health - Transgender Health Program. Available at: http://www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf. Accessed May 26, 2016.

18. TransYouth Family Allies. Empowering transgender youth & families. Available at: http://www.imatyfa.org/. Accessed May 26, 2016.

19. Human Rights Campaign. On our own: a survival guide for independent LGBTQ youth. Available at: https://www.hrc.org/resources/on-our-own-a-survival-guide-for-independent-lgbtq-youth. Accessed May 26, 2016.

20. Gay, Lesbian, Bisexual, and Transgender National Help Center. Available at: www.glbthotline.org. Accessed May 31, 2016.

21. University of California, San Francisco. Hormone administration. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-hormones.  Accessed December 12, 2015.

22. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013;201:996-1000.

23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.

24. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20-28.

25. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008;5:765-776.

26. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59:409-418.

27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-3473.

28. Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12-21.

29. Dickersin K, Munro MG, Clark M, et al.  Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized control trial. Obstet Gynecol. 2007;110:1279-1289.

30. Prasad P, Powell MC. Prospective observational study of thermablate endometrial ablation system as an outpatient procedure. J Minim Invasive Gynecol. 2008;15:476-479.

31. University of California, San Francisco. General prevention and screening. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-screening. Accessed June 24, 2015.

32. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995;82:341.

33. Meriggiola MC, Gava G. Endocrine care of transpeople part II: a review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83:607-615.

34. University of California, San Francisco. Surgical options. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-surgery. Accessed December 12, 2015.

Article PDF
Author and Disclosure Information

Abbas Hyderi, MD, MPH
Joseph Angel, MD
Morgan Madison, MD
L. Amanda Perry, MD
Leila Hagshenas, MD

University of Illinois at Chicago
ahyder2@uic.edu

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 65(7)
Publications
Topics
Page Number
450-452,457-461
Legacy Keywords
transgender, WPATH, World Professional Association for Transgender Health, female-to-male transition, male-to-female transition, LGBTQ, men's health, women's health, practice management, Abbas Hyderi, Joseph Angel, Morgan Madison, L. Amanda Perry, Leila Hagshenas
Sections
Author and Disclosure Information

Abbas Hyderi, MD, MPH
Joseph Angel, MD
Morgan Madison, MD
L. Amanda Perry, MD
Leila Hagshenas, MD

University of Illinois at Chicago
ahyder2@uic.edu

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

Abbas Hyderi, MD, MPH
Joseph Angel, MD
Morgan Madison, MD
L. Amanda Perry, MD
Leila Hagshenas, MD

University of Illinois at Chicago
ahyder2@uic.edu

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF
Related Articles
PRACTICE RECOMMENDATIONS

› Refer transgender patients to a mental health provider with experience in treating this patient population for diagnosis of gender dysphoria. B
› Confirm patients’ eligibility for hormone therapy and obtain informed consent before initiating it. B
› Treat minor adverse effects of hormone therapy whenever possible, as discontinuing the hormones may be detrimental to the well-being of patients in the process of transitioning. B
› Continue recommended screenings based on the sex the patient was assigned at birth, unless the organ or tissue in question has been surgically removed. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

 

Civil rights for the lesbian, gay, bisexual, and transgender population have advanced markedly in the past decade, and the medical community has gradually begun to address more of their health concerns. More recently, media attention to transgender individuals—although focused primarily on the “appropriate” use of restrooms—has encouraged many more to openly seek care.1,2

It is estimated that anywhere from 0.3% to 5% of the US population identifies as transgender.1-3 While awareness of this population has slowly increased, there is a paucity of research on the hormone treatment that is often essential to patients’ well-being. Studies of surgical options for transgender patients have been minimal, as well.

Family physicians are uniquely positioned to coordinate medical services and ensure continuity of care for transgender patients as they strive to become their authentic selves. Our goal in writing this article is to equip you with the tools to provide this patient population with sensitive, high-quality care (TABLE 1).4-7 Our focus is on the diagnosis of gender dysphoria (GD) and its medical and hormonal management—the realm of primary care providers. We briefly discuss surgical management of GD, as well.

 

 

Understanding and diagnosing gender dysphoria

Two classification systems are used for diagnoses related to GD: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed. (DSM-5)8 and the International Classification of Diseases, 10th Rev. (ICD-10).9

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

ICD-10 criteria use the term “gender identity disorder;” DSM-5 refers to “gender dysphoria” instead. It is important to emphasize that these classification systems represent an attempt to categorize a group of signs and symptoms that lead to distress for the patient, and are not meant to suggest that being transgender is pathological. In fact, in DSM-5—released in 2013—the American Psychiatric Association revised the terminology to emphasize that such individuals are not “disordered” by the nature of their identity, but rather by the distress that being transgender causes.8

For a diagnosis of GD in children, DSM-5 criteria include characteristics perceived to be incongruent between the child’s sex at birth and the self-identified gender based on preferred activities or dislike of his or her own sexual anatomy. The child must meet 6 or more of the following for at least 6 months:

  • a repeatedly stated desire to be, or insistence that he or she is, of the other gender
  • in boys, a preference for cross-dressing or simulating female attire; in girls, insistence on wearing only stereotypical masculine clothing
  • strong and persistent preferences for cross-gender roles in make-believe play or fantasy
  • a strong rejection of toys/games typically associated with the child’s sex
  • intense desire to participate in stereotypical games and pastimes of the other gender
  • strong preference for playmates of the other gender
  • a strong dislike of one’s sexual anatomy
  • a strong desire for the primary (eg, penis or vagina) or secondary (eg, menstruation) sex characteristics of the other gender.8

Adolescents and adults must meet 2 or more of the following for at least 6 months:

  • a noticeable incongruence between the gender that the patient sees themselves as and their sex characteristics
  • an intense need to do away with (or prevent) his or her primary or secondary sex features
  • an intense desire to have the primary and/or secondary sex features of the other gender
  • a deep desire to transform into another gender
  • a profound need for society to treat them as someone of the other gender
  • a powerful assurance of having the characteristic feelings and responses of the other gender.8

For children as well as adolescents and adults, the condition should cause the patient significant distress or significantly affect him or her socially, at work or school, and in other important areas of life.8

Is the patient a candidate for hormone therapy?

Two primary sources—Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7, issued by the World Professional Association for Transgender Health (WPATH)10 and Endocrine Treatment of Transsexual Persons11 by the Endocrine Society—offer clinical practice guidance based on evidence and expert opinion.

WPATH recommends that a mental health professional (MHP) experienced in transgender care diagnose GD to ensure that it is not mistaken for a psychiatric condition manifesting as altered gender identity. However, if no one with such experience is available or accessible in the region, it is reasonable for a primary care physician to make the diagnosis and consider initiating hormone therapy without a mental health referral,12 as the expected benefits outweigh the risks of nontreatment.13

Whether or not a MHP confirms a diagnosis of GD, it is still up to the treating physician to confirm the patient’s eligibility and readiness for hormone therapy: He or she should meet DSM-5 or ICD-10 criteria for GD, have no psychiatric comorbidity (eg, schizophrenia, body dysmorphic disorder, or uncontrolled bipolar disorder) likely to interfere with treatment, understand the expected outcomes and the social benefits and risks, and have indicated a willingness to take the hormones responsibly.

Historically, patients were required to have a documented Real-Life Experience (RLE), defined as having fully adopted the new gender role in everyday life for at least 3 months.10,11 This model has fallen out of favor, however, as it is unsupported by evidence and may place transgender individuals at physical and emotional risk.. Instead, readiness is confirmed by obtaining informed consent.12

Puberty may be suppressed with a gonadotropin-releasing hormone (GnRH) agonist in adolescents who have a GD diagnosis and are at Tanner stage 2 to 3 of puberty until age 16. At that point, hormone therapy consistent with their gender identification may be initiated.11 (See “How to help transgender teens.”11,14-20)

 

 

SIDEBAR
How to help transgender teens

Gender exploration is a normal part of childhood. Changes that occur during puberty cause many adolescents to question their ideas of gender and sexuality, but those with persistent gender nonconformity or extreme body dysphoria should receive medical and mental health care as early as possible.

A mental health professional (MHP) can help families create a safe, unconditionally accepting, and supportive environment in which their child can develop into his or her authentic self. A specialist in adolescent gender dysphoria (GD) should be consulted before initiating hormone therapy. Family physicians are well positioned to provide follow-up and ongoing care.

Initiating hormone suppression for adolescents with GD early in puberty can greatly reduce the emotional trauma, as well as the need for surgery related to unwanted secondary sex characteristics. Hormone suppression also gives adolescents more time to explore their gender nonconformity and developmental needs. Treatment with a gonadotropin-releasing hormone agonist such as leuprolide or histrelin can be initiated for adolescents in Tanner Stage 2, assessed by hormone levels, as well as breast, testicle, and pubic hair development (childgrowthfoundation.org/CMS/FILES/Puberty_and_the_Tanner_Stages.pdf), to suppress ongoing puberty.11,14

The effects of puberty blockers are reversible. If preferred, however, medication management can allow teens to progress directly from hormone suppression to the puberty of their self-identified gender once initiation of adult transgender hormone therapy is started—typically around the age of 16.11

Some adolescents may seek medical care well after puberty has begun. It is possible to use hormone suppression therapy after a teen has started to develop unwanted secondary sex characteristics. However, such patients may get less benefit from puberty blockers and often derive more benefit from initiation of cross-gender hormones.

Safety—a broader perspective. Regardless of medical treatment or the age at which treatment is begun, parents and patients need to be reminded that gender transition is about more than hormones. It is crucial that either the MHP or primary care physician, or both, address safety issues and work with the transgender individual to create a comprehensive plan for his or her health, safety, and social well-being.

Psychosocial concerns for transgender youth are vast, often encompassing rejection by peers and potentially, by family and authority figures; harassment; physical, emotional, and sexual abuse; inadequate housing; legal problems; lack of financial support; and educational difficulties.15 School is a particular source of concern. A survey by the Gay, Lesbian and Straight Education Network found, for instance, that nearly 9 in 10 transgender youth had been verbally harassed at school because of their gender expression. More than half also reported being physically harassed (eg, pushed or shoved).15

Bathroom use in schools is a major issue, as well, with transgender youth often prevented from using the restroom or locker room that coincides with their gender identity. In May, 11 states filed a lawsuit against the Obama administration for directing schools to allow such students to do so or risk the loss of federal funds.16

Tools and support. In 2006, the Vancouver Coastal Health, Transcend Transgender Support & Education Society, and the Canadian Rainbow Health Coalition published guidelines for the care of transgender adolescents, including a modification of the HEEADSSS tool (used to assess teens’ psychosocial well-being) specific to transgender youth.17 (See http://www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf.) The tool can help you identify possible areas of concern and intervene, as needed.

If a patient reports feeling especially vulnerable at school, for example, encourage him or her to identify supportive friends, family members, teachers, or school counselors who can help create safe networks. Suggest that a teen who feels threatened travel in groups whenever possible. Stress to family members that their acceptance is key to nurturing positive feelings in youth with GD. And refer patients and parents to organizations that provide information and support.

Chief among them are Trans Youth Family Allies18 (www.imatyfa.org), which provides resources for parents, educators, and health care practitioners; the Human Rights Campaign, which has created a survival guide for gay and transgender youth who are forced to seek independent living19 (available at hrc-assets.s3-website-us-east-1.amazonaws.com//files/assets/resources/HRC-OnOurOwn-LGBTQYouth.pdf), and the Gay, Lesbian, Bisexual, and Transgender National Help Center, which hosts a GLBT national hotline (888-843-4564) and a weekly Trans Teen Online Talk Group.20 For more information about the online talk group, go to glbthotline.org and click on “transteens.”

 

 

Beginning the transition

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

For patients interested in medical interventions, possible therapies include cross-sex hormone administration and gender-affirming surgery. Both are aimed at making the physical and the psychological more congruent. Hormone treatment (TABLE 2)10,11,21 is often essential to reduce the distress of individuals with GD and to help them feel comfortable in their own body. Psychological conditions, such as depression, tend to improve as the transitioning process gets underway.22

 

 

 

Female-to-male transition

CASE 1

Jennie R, a 55-year-old postmenopausal patient, comes to your office for an annual exam. Although you’ve been her primary care physician for several years, she confides for the first time that she has never been comfortable as a woman. “I’ve always felt that my body didn’t belong to me,” the patient admits, and goes on to say that for the last several years she has been living as a man. Jennie R says she is ready to start hormone therapy to assist with the gender transition and asks about the process, the benefits and risks, and how quickly she can expect to achieve the desired results.

If Jennie R were your patient, how would you respond?

Masculinizing hormone treatment

As you would explain to a patient like Jennie R, the goal of hormone therapy is to suppress the effects of the sex assigned at birth and replace them with those of the desired gender. In the case of a female transitioning to a male (known as a transman), masculinizing hormones would promote growth of facial and body hair, cessation of menses, increased muscle mass, deepening of the voice, and clitoral enlargement.11,23,24

Physical changes induced by masculinizing hormone therapy have an expected onset of one to 6 months and achieve maximum effect in approximately 2 to 5 years.10,11 Although there have been no controlled clinical trials evaluating the safety or efficacy of any transitional hormone regimen, WPATH and the Center of Excellence for Transgender Health at the University of California, San Francisco, suggest initiating intramuscular or transdermal testosterone at increasing doses until normal physiologic male testosterone levels between 350 and 700 ng/dL are achieved, or until cessation of menses.13,25-28 The dose at which either, or both, occur should be continued as long-term maintenance therapy. Medroxyprogesterone can be added, if necessary for menstrual cessation, and a GnRH agonist or endometrial ablation can be used for refractory uterine bleeding.29,30

Psychological conditions such as depression tend to improve when a transgender individual begins the transitioning process.

Testosterone is not a contraceptive. It is important to emphasize to transmen like Jennie that they remain at risk of pregnancy if they are having sex with fertile males. Caution patients not to assume that the possibility of pregnancy ends when menses stop.

Treat minor adverse effects. Adverse effects of masculinizing hormones include vaginal atrophy, fat redistribution and weight gain, polycythemia, acne, scalp hair loss, sleep apnea, elevated liver enzymes, hyperlipidemia, cardiovascular disease, diabetes, and bone density loss. Increased risk of cancer of the female organs has not been proven.10,11 It is reasonable to treat minor adverse effects after reviewing the risks vs benefits of doing so, as discontinuing hormone therapy could be detrimental to the well-being of transitioning patients.11

There are absolute contraindications to masculinizing hormone therapy, however, including pregnancy, unstable coronary artery disease, and untreated polycythemia with a hematocrit >55%.10

Monitoring is essential. Patients receiving masculinizing hormone therapy should be monitored every 3 months during the first year and once or twice a year thereafter, with a focused history (including mood symptoms), physical exam (including weight and blood pressure), and labs (including complete blood count, liver function, renal function, and lipids) at each visit.11,23 Some clinicians also check estradiol levels until they fall below 50 pg/mL,23,27 while others take the cessation of uterine bleeding for >6 months as an indicator of estrogen suppression.

Remind patients of the need for contraception, pointing out that a male transitioning to a female may still impregnate a female partner and a female transitioning to a male may still conceive.

Preventive health measures continue. Routine screening should continue, based on the patient’s assigned sex at birth. Thus, a transman who has not had a hysterectomy still needs Pap smears, mammograms if the patient has not had a double mastectomy, and bone mineral density (BMD) testing to screen for osteoporosis.31,32 Some experts recommend starting to test BMD at age 50 for patients receiving masculinizing hormones, given the unknown effect of testosterone on bone density.11,31,32

CASE 1

The first question for a transgender patient is about his or her current gender identity, but Jennie R has already reported living as a man. So you start by asking “What name do you prefer to use?” and “Do you prefer to be referred to with male or female pronouns?”

The patient tells you that he sees himself as a man, he wants to be called Jeff, and he prefers male pronouns. You explain that you believe he has gender dysphoria and would benefit from hormone therapy, but it is important to confirm this diagnosis with a MHP. You explain that testosterone can be prescribed for masculinizing effects, and describe the expected effects—more facial and body hair, a deeper voice and greater muscle mass, among others—and review the likely time frame

You also discuss the risks of masculinizing hormones (hyperlipidemia, cardiovascular disease, diabetes, and loss of bone density) that will need to be monitored. Before he leaves, you give him the name of a MHP who is experienced in transgender care and tell him to make a follow-up appointment with you after he has seen her. At the conclusion of the visit, you make a note of the patient’s name and gender identity in the chart and inform the staff of the changes.

 

 

Male-to-female transition

CASE 2

Before heading into your office to talk to a new patient named Carl S, you glance at his chart and see that he is a healthy 21-year-old who has come in for a routine physical. When you enter the room, you find Carl wearing a dress, heels, and make-up. After confirming that you have the right patient, you ask, “What is your current gender identity?” “Female,” says Carl, who indicates that she now goes by Carol. The patient has no medical problems, surgical history, or significant family history, but reports that she has been taking spironolactone and estrogen for the past 3 years. Carol also says she has a new female partner and is having unprotected sexual activity.

Feminizing hormone treatment

The desired effects of feminizing hormones include voice change, decreased hair growth, breast growth, body fat redistribution, decreased muscle mass, skin softening, decreased oiliness of skin and hair, and a decrease in spontaneous erections, testicular volume, and sperm production.10,11 The onset of feminizing effects ranges from one month to one year and the expected maximum effect occurs anywhere between 3 months and 5 years.10,11 Regimens usually include anti-androgen agents and estrogen.13,26-28

The medications that have been most studied with anti-androgenic effects include spironolactone and 5-alpha reductase inhibitors (5-ARIs) such as finasteride. Spironolactone inhibits testosterone secretion and inhibits androgen binding to androgen receptors; 5-ARIs block the conversion of testosterone to 5-alpha-dihydrotestosterone, the more active form.

Males transitioning to females should undergo breast cancer screening beginning at 40 to 50 years of age if they remain on hormone therapy.

Estrogen can be administered via oral, sublingual, transdermal, or intramuscular route, but parenteral formulations are preferred to avoid first-pass metabolism. The serum estradiol target is similar to the mean daily level of premenopausal women (<200 pg/mL) and the level of testosterone should be in the normal female range (<55 ng/dL).13,26-28

The selection of medications should be individualized for each patient. Comorbidities must be considered, as well as the risk of adverse effects, which include venous thromboembolism, elevated liver enzymes, breast cancer, cardiovascular disease, diabetes, hyperprolactinemia, weight gain, gallstones, cerebrovascular disease, and severe migraine headaches.10,11 Estrogen therapy is not reported to induce hypertrophy or premalignant changes in the prostate.33 As is the case for masculinizing hormones, feminizing hormone therapy should be continued indefinitely for long-term effects.

Frequent monitoring is recommended. Patients on feminizing hormones (transwomen) should be seen every 2 to 3 months in the first year and monitored once or twice a year thereafter. Serum testosterone and estradiol levels should initially be monitored every 3 months; serum electrolytes, specifically potassium, should be monitored every 2 to 3 months in the first year until stable.

CASE 2

You recommend that Carol S be screened annually for sexually transmitted diseases, as you would for any 21-year-old patient. You point out, too, that while estrogen and androgen-suppressing therapy decrease sperm production, there is a possibility that the patient could impregnate a female partner and recommend that contraception be used if the couple is not trying to conceive.

You also discuss the risks and benefits of hormone therapy and reasonable expectations of continued treatment. You ask Carol to schedule a follow-up visit in 6 months, as her hormone regimen is stable. Finally, if the patient remains on hormone therapy, you mention that the only screening unique to men transitioning to women is for breast cancer, which should begin at 40 to 50 years of age (as it is for all women).

Gender-affirming surgical options

Nearly 9 in 10 transgender youth report being verbally harassed at school because of their gender expression. More than half report being physically harassed.

Surgical management of transgender patients is not within the scope of family medicine. But it is essential to know what procedures are available as you may have occasion to advocate for patients during the surgical referral process and possibly to provide postoperative care.

For transmen, surgical options include chest reconstruction, hysterectomy/oophorectomy, metoidioplasty (using the clitoris to surgically approximate a penis), phalloplasty, scrotoplasty, urethroplasty, and vaginectomy.10,34 The surgeries available for transwomen are orchiectomy, vaginoplasty, penectomy, breast augmentation, thyroid chondroplasty and voice surgery, and facial feminization.10,34 Keep in mind that not all transgender individuals desire surgery as part of the transitioning process.

CORRESPONDENCE
Abbas Hyderi, MD, MPH, 1919 West Taylor Street, M/C 663, Chicago, IL 60612; ahyder2@uic.edu.

The authors would like to acknowledge the assistance of Michelle Forcier, MD, MPH, and Karen S. Bernstein, MD, MPH, in the preparation of this manuscript. 

PRACTICE RECOMMENDATIONS

› Refer transgender patients to a mental health provider with experience in treating this patient population for diagnosis of gender dysphoria. B
› Confirm patients’ eligibility for hormone therapy and obtain informed consent before initiating it. B
› Treat minor adverse effects of hormone therapy whenever possible, as discontinuing the hormones may be detrimental to the well-being of patients in the process of transitioning. B
› Continue recommended screenings based on the sex the patient was assigned at birth, unless the organ or tissue in question has been surgically removed. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series

 

Civil rights for the lesbian, gay, bisexual, and transgender population have advanced markedly in the past decade, and the medical community has gradually begun to address more of their health concerns. More recently, media attention to transgender individuals—although focused primarily on the “appropriate” use of restrooms—has encouraged many more to openly seek care.1,2

It is estimated that anywhere from 0.3% to 5% of the US population identifies as transgender.1-3 While awareness of this population has slowly increased, there is a paucity of research on the hormone treatment that is often essential to patients’ well-being. Studies of surgical options for transgender patients have been minimal, as well.

Family physicians are uniquely positioned to coordinate medical services and ensure continuity of care for transgender patients as they strive to become their authentic selves. Our goal in writing this article is to equip you with the tools to provide this patient population with sensitive, high-quality care (TABLE 1).4-7 Our focus is on the diagnosis of gender dysphoria (GD) and its medical and hormonal management—the realm of primary care providers. We briefly discuss surgical management of GD, as well.

 

 

Understanding and diagnosing gender dysphoria

Two classification systems are used for diagnoses related to GD: the Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed. (DSM-5)8 and the International Classification of Diseases, 10th Rev. (ICD-10).9

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

ICD-10 criteria use the term “gender identity disorder;” DSM-5 refers to “gender dysphoria” instead. It is important to emphasize that these classification systems represent an attempt to categorize a group of signs and symptoms that lead to distress for the patient, and are not meant to suggest that being transgender is pathological. In fact, in DSM-5—released in 2013—the American Psychiatric Association revised the terminology to emphasize that such individuals are not “disordered” by the nature of their identity, but rather by the distress that being transgender causes.8

For a diagnosis of GD in children, DSM-5 criteria include characteristics perceived to be incongruent between the child’s sex at birth and the self-identified gender based on preferred activities or dislike of his or her own sexual anatomy. The child must meet 6 or more of the following for at least 6 months:

  • a repeatedly stated desire to be, or insistence that he or she is, of the other gender
  • in boys, a preference for cross-dressing or simulating female attire; in girls, insistence on wearing only stereotypical masculine clothing
  • strong and persistent preferences for cross-gender roles in make-believe play or fantasy
  • a strong rejection of toys/games typically associated with the child’s sex
  • intense desire to participate in stereotypical games and pastimes of the other gender
  • strong preference for playmates of the other gender
  • a strong dislike of one’s sexual anatomy
  • a strong desire for the primary (eg, penis or vagina) or secondary (eg, menstruation) sex characteristics of the other gender.8

Adolescents and adults must meet 2 or more of the following for at least 6 months:

  • a noticeable incongruence between the gender that the patient sees themselves as and their sex characteristics
  • an intense need to do away with (or prevent) his or her primary or secondary sex features
  • an intense desire to have the primary and/or secondary sex features of the other gender
  • a deep desire to transform into another gender
  • a profound need for society to treat them as someone of the other gender
  • a powerful assurance of having the characteristic feelings and responses of the other gender.8

For children as well as adolescents and adults, the condition should cause the patient significant distress or significantly affect him or her socially, at work or school, and in other important areas of life.8

Is the patient a candidate for hormone therapy?

Two primary sources—Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7, issued by the World Professional Association for Transgender Health (WPATH)10 and Endocrine Treatment of Transsexual Persons11 by the Endocrine Society—offer clinical practice guidance based on evidence and expert opinion.

WPATH recommends that a mental health professional (MHP) experienced in transgender care diagnose GD to ensure that it is not mistaken for a psychiatric condition manifesting as altered gender identity. However, if no one with such experience is available or accessible in the region, it is reasonable for a primary care physician to make the diagnosis and consider initiating hormone therapy without a mental health referral,12 as the expected benefits outweigh the risks of nontreatment.13

Whether or not a MHP confirms a diagnosis of GD, it is still up to the treating physician to confirm the patient’s eligibility and readiness for hormone therapy: He or she should meet DSM-5 or ICD-10 criteria for GD, have no psychiatric comorbidity (eg, schizophrenia, body dysmorphic disorder, or uncontrolled bipolar disorder) likely to interfere with treatment, understand the expected outcomes and the social benefits and risks, and have indicated a willingness to take the hormones responsibly.

Historically, patients were required to have a documented Real-Life Experience (RLE), defined as having fully adopted the new gender role in everyday life for at least 3 months.10,11 This model has fallen out of favor, however, as it is unsupported by evidence and may place transgender individuals at physical and emotional risk.. Instead, readiness is confirmed by obtaining informed consent.12

Puberty may be suppressed with a gonadotropin-releasing hormone (GnRH) agonist in adolescents who have a GD diagnosis and are at Tanner stage 2 to 3 of puberty until age 16. At that point, hormone therapy consistent with their gender identification may be initiated.11 (See “How to help transgender teens.”11,14-20)

 

 

SIDEBAR
How to help transgender teens

Gender exploration is a normal part of childhood. Changes that occur during puberty cause many adolescents to question their ideas of gender and sexuality, but those with persistent gender nonconformity or extreme body dysphoria should receive medical and mental health care as early as possible.

A mental health professional (MHP) can help families create a safe, unconditionally accepting, and supportive environment in which their child can develop into his or her authentic self. A specialist in adolescent gender dysphoria (GD) should be consulted before initiating hormone therapy. Family physicians are well positioned to provide follow-up and ongoing care.

Initiating hormone suppression for adolescents with GD early in puberty can greatly reduce the emotional trauma, as well as the need for surgery related to unwanted secondary sex characteristics. Hormone suppression also gives adolescents more time to explore their gender nonconformity and developmental needs. Treatment with a gonadotropin-releasing hormone agonist such as leuprolide or histrelin can be initiated for adolescents in Tanner Stage 2, assessed by hormone levels, as well as breast, testicle, and pubic hair development (childgrowthfoundation.org/CMS/FILES/Puberty_and_the_Tanner_Stages.pdf), to suppress ongoing puberty.11,14

The effects of puberty blockers are reversible. If preferred, however, medication management can allow teens to progress directly from hormone suppression to the puberty of their self-identified gender once initiation of adult transgender hormone therapy is started—typically around the age of 16.11

Some adolescents may seek medical care well after puberty has begun. It is possible to use hormone suppression therapy after a teen has started to develop unwanted secondary sex characteristics. However, such patients may get less benefit from puberty blockers and often derive more benefit from initiation of cross-gender hormones.

Safety—a broader perspective. Regardless of medical treatment or the age at which treatment is begun, parents and patients need to be reminded that gender transition is about more than hormones. It is crucial that either the MHP or primary care physician, or both, address safety issues and work with the transgender individual to create a comprehensive plan for his or her health, safety, and social well-being.

Psychosocial concerns for transgender youth are vast, often encompassing rejection by peers and potentially, by family and authority figures; harassment; physical, emotional, and sexual abuse; inadequate housing; legal problems; lack of financial support; and educational difficulties.15 School is a particular source of concern. A survey by the Gay, Lesbian and Straight Education Network found, for instance, that nearly 9 in 10 transgender youth had been verbally harassed at school because of their gender expression. More than half also reported being physically harassed (eg, pushed or shoved).15

Bathroom use in schools is a major issue, as well, with transgender youth often prevented from using the restroom or locker room that coincides with their gender identity. In May, 11 states filed a lawsuit against the Obama administration for directing schools to allow such students to do so or risk the loss of federal funds.16

Tools and support. In 2006, the Vancouver Coastal Health, Transcend Transgender Support & Education Society, and the Canadian Rainbow Health Coalition published guidelines for the care of transgender adolescents, including a modification of the HEEADSSS tool (used to assess teens’ psychosocial well-being) specific to transgender youth.17 (See http://www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf.) The tool can help you identify possible areas of concern and intervene, as needed.

If a patient reports feeling especially vulnerable at school, for example, encourage him or her to identify supportive friends, family members, teachers, or school counselors who can help create safe networks. Suggest that a teen who feels threatened travel in groups whenever possible. Stress to family members that their acceptance is key to nurturing positive feelings in youth with GD. And refer patients and parents to organizations that provide information and support.

Chief among them are Trans Youth Family Allies18 (www.imatyfa.org), which provides resources for parents, educators, and health care practitioners; the Human Rights Campaign, which has created a survival guide for gay and transgender youth who are forced to seek independent living19 (available at hrc-assets.s3-website-us-east-1.amazonaws.com//files/assets/resources/HRC-OnOurOwn-LGBTQYouth.pdf), and the Gay, Lesbian, Bisexual, and Transgender National Help Center, which hosts a GLBT national hotline (888-843-4564) and a weekly Trans Teen Online Talk Group.20 For more information about the online talk group, go to glbthotline.org and click on “transteens.”

 

 

Beginning the transition

The transitioning process is a complex and individualized journey that can include inward or outward change, or both.

For patients interested in medical interventions, possible therapies include cross-sex hormone administration and gender-affirming surgery. Both are aimed at making the physical and the psychological more congruent. Hormone treatment (TABLE 2)10,11,21 is often essential to reduce the distress of individuals with GD and to help them feel comfortable in their own body. Psychological conditions, such as depression, tend to improve as the transitioning process gets underway.22

 

 

 

Female-to-male transition

CASE 1

Jennie R, a 55-year-old postmenopausal patient, comes to your office for an annual exam. Although you’ve been her primary care physician for several years, she confides for the first time that she has never been comfortable as a woman. “I’ve always felt that my body didn’t belong to me,” the patient admits, and goes on to say that for the last several years she has been living as a man. Jennie R says she is ready to start hormone therapy to assist with the gender transition and asks about the process, the benefits and risks, and how quickly she can expect to achieve the desired results.

If Jennie R were your patient, how would you respond?

Masculinizing hormone treatment

As you would explain to a patient like Jennie R, the goal of hormone therapy is to suppress the effects of the sex assigned at birth and replace them with those of the desired gender. In the case of a female transitioning to a male (known as a transman), masculinizing hormones would promote growth of facial and body hair, cessation of menses, increased muscle mass, deepening of the voice, and clitoral enlargement.11,23,24

Physical changes induced by masculinizing hormone therapy have an expected onset of one to 6 months and achieve maximum effect in approximately 2 to 5 years.10,11 Although there have been no controlled clinical trials evaluating the safety or efficacy of any transitional hormone regimen, WPATH and the Center of Excellence for Transgender Health at the University of California, San Francisco, suggest initiating intramuscular or transdermal testosterone at increasing doses until normal physiologic male testosterone levels between 350 and 700 ng/dL are achieved, or until cessation of menses.13,25-28 The dose at which either, or both, occur should be continued as long-term maintenance therapy. Medroxyprogesterone can be added, if necessary for menstrual cessation, and a GnRH agonist or endometrial ablation can be used for refractory uterine bleeding.29,30

Psychological conditions such as depression tend to improve when a transgender individual begins the transitioning process.

Testosterone is not a contraceptive. It is important to emphasize to transmen like Jennie that they remain at risk of pregnancy if they are having sex with fertile males. Caution patients not to assume that the possibility of pregnancy ends when menses stop.

Treat minor adverse effects. Adverse effects of masculinizing hormones include vaginal atrophy, fat redistribution and weight gain, polycythemia, acne, scalp hair loss, sleep apnea, elevated liver enzymes, hyperlipidemia, cardiovascular disease, diabetes, and bone density loss. Increased risk of cancer of the female organs has not been proven.10,11 It is reasonable to treat minor adverse effects after reviewing the risks vs benefits of doing so, as discontinuing hormone therapy could be detrimental to the well-being of transitioning patients.11

There are absolute contraindications to masculinizing hormone therapy, however, including pregnancy, unstable coronary artery disease, and untreated polycythemia with a hematocrit >55%.10

Monitoring is essential. Patients receiving masculinizing hormone therapy should be monitored every 3 months during the first year and once or twice a year thereafter, with a focused history (including mood symptoms), physical exam (including weight and blood pressure), and labs (including complete blood count, liver function, renal function, and lipids) at each visit.11,23 Some clinicians also check estradiol levels until they fall below 50 pg/mL,23,27 while others take the cessation of uterine bleeding for >6 months as an indicator of estrogen suppression.

Remind patients of the need for contraception, pointing out that a male transitioning to a female may still impregnate a female partner and a female transitioning to a male may still conceive.

Preventive health measures continue. Routine screening should continue, based on the patient’s assigned sex at birth. Thus, a transman who has not had a hysterectomy still needs Pap smears, mammograms if the patient has not had a double mastectomy, and bone mineral density (BMD) testing to screen for osteoporosis.31,32 Some experts recommend starting to test BMD at age 50 for patients receiving masculinizing hormones, given the unknown effect of testosterone on bone density.11,31,32

CASE 1

The first question for a transgender patient is about his or her current gender identity, but Jennie R has already reported living as a man. So you start by asking “What name do you prefer to use?” and “Do you prefer to be referred to with male or female pronouns?”

The patient tells you that he sees himself as a man, he wants to be called Jeff, and he prefers male pronouns. You explain that you believe he has gender dysphoria and would benefit from hormone therapy, but it is important to confirm this diagnosis with a MHP. You explain that testosterone can be prescribed for masculinizing effects, and describe the expected effects—more facial and body hair, a deeper voice and greater muscle mass, among others—and review the likely time frame

You also discuss the risks of masculinizing hormones (hyperlipidemia, cardiovascular disease, diabetes, and loss of bone density) that will need to be monitored. Before he leaves, you give him the name of a MHP who is experienced in transgender care and tell him to make a follow-up appointment with you after he has seen her. At the conclusion of the visit, you make a note of the patient’s name and gender identity in the chart and inform the staff of the changes.

 

 

Male-to-female transition

CASE 2

Before heading into your office to talk to a new patient named Carl S, you glance at his chart and see that he is a healthy 21-year-old who has come in for a routine physical. When you enter the room, you find Carl wearing a dress, heels, and make-up. After confirming that you have the right patient, you ask, “What is your current gender identity?” “Female,” says Carl, who indicates that she now goes by Carol. The patient has no medical problems, surgical history, or significant family history, but reports that she has been taking spironolactone and estrogen for the past 3 years. Carol also says she has a new female partner and is having unprotected sexual activity.

Feminizing hormone treatment

The desired effects of feminizing hormones include voice change, decreased hair growth, breast growth, body fat redistribution, decreased muscle mass, skin softening, decreased oiliness of skin and hair, and a decrease in spontaneous erections, testicular volume, and sperm production.10,11 The onset of feminizing effects ranges from one month to one year and the expected maximum effect occurs anywhere between 3 months and 5 years.10,11 Regimens usually include anti-androgen agents and estrogen.13,26-28

The medications that have been most studied with anti-androgenic effects include spironolactone and 5-alpha reductase inhibitors (5-ARIs) such as finasteride. Spironolactone inhibits testosterone secretion and inhibits androgen binding to androgen receptors; 5-ARIs block the conversion of testosterone to 5-alpha-dihydrotestosterone, the more active form.

Males transitioning to females should undergo breast cancer screening beginning at 40 to 50 years of age if they remain on hormone therapy.

Estrogen can be administered via oral, sublingual, transdermal, or intramuscular route, but parenteral formulations are preferred to avoid first-pass metabolism. The serum estradiol target is similar to the mean daily level of premenopausal women (<200 pg/mL) and the level of testosterone should be in the normal female range (<55 ng/dL).13,26-28

The selection of medications should be individualized for each patient. Comorbidities must be considered, as well as the risk of adverse effects, which include venous thromboembolism, elevated liver enzymes, breast cancer, cardiovascular disease, diabetes, hyperprolactinemia, weight gain, gallstones, cerebrovascular disease, and severe migraine headaches.10,11 Estrogen therapy is not reported to induce hypertrophy or premalignant changes in the prostate.33 As is the case for masculinizing hormones, feminizing hormone therapy should be continued indefinitely for long-term effects.

Frequent monitoring is recommended. Patients on feminizing hormones (transwomen) should be seen every 2 to 3 months in the first year and monitored once or twice a year thereafter. Serum testosterone and estradiol levels should initially be monitored every 3 months; serum electrolytes, specifically potassium, should be monitored every 2 to 3 months in the first year until stable.

CASE 2

You recommend that Carol S be screened annually for sexually transmitted diseases, as you would for any 21-year-old patient. You point out, too, that while estrogen and androgen-suppressing therapy decrease sperm production, there is a possibility that the patient could impregnate a female partner and recommend that contraception be used if the couple is not trying to conceive.

You also discuss the risks and benefits of hormone therapy and reasonable expectations of continued treatment. You ask Carol to schedule a follow-up visit in 6 months, as her hormone regimen is stable. Finally, if the patient remains on hormone therapy, you mention that the only screening unique to men transitioning to women is for breast cancer, which should begin at 40 to 50 years of age (as it is for all women).

Gender-affirming surgical options

Nearly 9 in 10 transgender youth report being verbally harassed at school because of their gender expression. More than half report being physically harassed.

Surgical management of transgender patients is not within the scope of family medicine. But it is essential to know what procedures are available as you may have occasion to advocate for patients during the surgical referral process and possibly to provide postoperative care.

For transmen, surgical options include chest reconstruction, hysterectomy/oophorectomy, metoidioplasty (using the clitoris to surgically approximate a penis), phalloplasty, scrotoplasty, urethroplasty, and vaginectomy.10,34 The surgeries available for transwomen are orchiectomy, vaginoplasty, penectomy, breast augmentation, thyroid chondroplasty and voice surgery, and facial feminization.10,34 Keep in mind that not all transgender individuals desire surgery as part of the transitioning process.

CORRESPONDENCE
Abbas Hyderi, MD, MPH, 1919 West Taylor Street, M/C 663, Chicago, IL 60612; ahyder2@uic.edu.

The authors would like to acknowledge the assistance of Michelle Forcier, MD, MPH, and Karen S. Bernstein, MD, MPH, in the preparation of this manuscript. 

References

1. Pew Research Center. A survey of LGBT Americans: attitudes, experiences and values in changing times. Available at: http://www.pewsocialtrends.org/2013/06/13/a-survey-of-lgbt-americans. Accessed June 24, 2015.

2. Gates GJ. How many people are lesbian, gay, bisexual and transgender? Available at: http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf. Accessed May 25, 2016.

3. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav. 1996;25:589-600.

4. Bhola S. An ally’s guide to terminology: talking about LGBT people & equality. Available at: http://www.glaad.org/2011/07/28/an-allys-guide-to-terminology-talking-about-lgbt-people-equality. Accessed June 24, 2015.

5. University of California, San Francisco. Transgender terminology. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/tcoe?page=protocol-terminology. Accessed June 24, 2015.

6. Istar A. How queer! the development of gender identity and sexual orientation in LGBTQ-headed families. Fam Process. 2010;49:268-290.

7. Goins ES, Pye D. Check the box that best describes you: reflexively managing theory and praxis in LGBTQ health communication research. Health Commun. 2013;28:397-407.

8. American Psychiatric Association. Gender dysphoria. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association. 2013:451-459.

9. World Health Organization. The International Classification of Diseases, 10th rev. Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992; Geneva.

10. Coleman E, Bockting W, Botzer M, et al; World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgender. 2011;13:165–232.

11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine Treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline. J Clin Endo Metabol. 2009;94:3132–3154.

12. University of California, San Francisco. Assessing readiness for hormones. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/tcoe?page=protocol-hormone-ready. Accessed June 24, 2015.

13. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):S31-S614.

14. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20:725-732.

15. Gay, Lesbian, and Straight Education Network (GLSEN). Harsh realities. The experiences of transgender youth in our nation’s schools. Available at: https://www.glsen.org/sites/default/files/Harsh%20Realities.pdf. Accessed May 29, 2016.

16. Berman M, Balingit M. Eleven states sue Obama administration over bathroom guidance for transgender students. May 25, 2016. Washington Post. Available at: https://www.washingtonpost.com/news/post-nation/wp/2016/05/25/texas-governor-says-state-will-sue-obama-administration-over-bathroom-directive/. Accessed May 31, 2016.

17. de Vries AL, Cohen-Kettenis PT, Delemarre-van de Waal H. Clinical management of gender dysphoria in adolescents. 2006. Vancouver Coastal Health - Transgender Health Program. Available at: http://www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf. Accessed May 26, 2016.

18. TransYouth Family Allies. Empowering transgender youth & families. Available at: http://www.imatyfa.org/. Accessed May 26, 2016.

19. Human Rights Campaign. On our own: a survival guide for independent LGBTQ youth. Available at: https://www.hrc.org/resources/on-our-own-a-survival-guide-for-independent-lgbtq-youth. Accessed May 26, 2016.

20. Gay, Lesbian, Bisexual, and Transgender National Help Center. Available at: www.glbthotline.org. Accessed May 31, 2016.

21. University of California, San Francisco. Hormone administration. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-hormones.  Accessed December 12, 2015.

22. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013;201:996-1000.

23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.

24. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20-28.

25. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008;5:765-776.

26. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59:409-418.

27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-3473.

28. Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12-21.

29. Dickersin K, Munro MG, Clark M, et al.  Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized control trial. Obstet Gynecol. 2007;110:1279-1289.

30. Prasad P, Powell MC. Prospective observational study of thermablate endometrial ablation system as an outpatient procedure. J Minim Invasive Gynecol. 2008;15:476-479.

31. University of California, San Francisco. General prevention and screening. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-screening. Accessed June 24, 2015.

32. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995;82:341.

33. Meriggiola MC, Gava G. Endocrine care of transpeople part II: a review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83:607-615.

34. University of California, San Francisco. Surgical options. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-surgery. Accessed December 12, 2015.

References

1. Pew Research Center. A survey of LGBT Americans: attitudes, experiences and values in changing times. Available at: http://www.pewsocialtrends.org/2013/06/13/a-survey-of-lgbt-americans. Accessed June 24, 2015.

2. Gates GJ. How many people are lesbian, gay, bisexual and transgender? Available at: http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf. Accessed May 25, 2016.

3. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav. 1996;25:589-600.

4. Bhola S. An ally’s guide to terminology: talking about LGBT people & equality. Available at: http://www.glaad.org/2011/07/28/an-allys-guide-to-terminology-talking-about-lgbt-people-equality. Accessed June 24, 2015.

5. University of California, San Francisco. Transgender terminology. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/tcoe?page=protocol-terminology. Accessed June 24, 2015.

6. Istar A. How queer! the development of gender identity and sexual orientation in LGBTQ-headed families. Fam Process. 2010;49:268-290.

7. Goins ES, Pye D. Check the box that best describes you: reflexively managing theory and praxis in LGBTQ health communication research. Health Commun. 2013;28:397-407.

8. American Psychiatric Association. Gender dysphoria. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association. 2013:451-459.

9. World Health Organization. The International Classification of Diseases, 10th rev. Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1992; Geneva.

10. Coleman E, Bockting W, Botzer M, et al; World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. Int J Transgender. 2011;13:165–232.

11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine Treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline. J Clin Endo Metabol. 2009;94:3132–3154.

12. University of California, San Francisco. Assessing readiness for hormones. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/tcoe?page=protocol-hormone-ready. Accessed June 24, 2015.

13. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(suppl 2):S31-S614.

14. Hembree WC. Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am. 2011;20:725-732.

15. Gay, Lesbian, and Straight Education Network (GLSEN). Harsh realities. The experiences of transgender youth in our nation’s schools. Available at: https://www.glsen.org/sites/default/files/Harsh%20Realities.pdf. Accessed May 29, 2016.

16. Berman M, Balingit M. Eleven states sue Obama administration over bathroom guidance for transgender students. May 25, 2016. Washington Post. Available at: https://www.washingtonpost.com/news/post-nation/wp/2016/05/25/texas-governor-says-state-will-sue-obama-administration-over-bathroom-directive/. Accessed May 31, 2016.

17. de Vries AL, Cohen-Kettenis PT, Delemarre-van de Waal H. Clinical management of gender dysphoria in adolescents. 2006. Vancouver Coastal Health - Transgender Health Program. Available at: http://www.amsa.org/wp-content/uploads/2015/04/CaringForTransgenderAdolescents.pdf. Accessed May 26, 2016.

18. TransYouth Family Allies. Empowering transgender youth & families. Available at: http://www.imatyfa.org/. Accessed May 26, 2016.

19. Human Rights Campaign. On our own: a survival guide for independent LGBTQ youth. Available at: https://www.hrc.org/resources/on-our-own-a-survival-guide-for-independent-lgbtq-youth. Accessed May 26, 2016.

20. Gay, Lesbian, Bisexual, and Transgender National Help Center. Available at: www.glbthotline.org. Accessed May 31, 2016.

21. University of California, San Francisco. Hormone administration. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-hormones.  Accessed December 12, 2015.

22. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013;201:996-1000.

23. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.

24. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20-28.

25. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008;5:765-776.

26. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf). 2003;59:409-418.

27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467-3473.

28. Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12-21.

29. Dickersin K, Munro MG, Clark M, et al.  Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized control trial. Obstet Gynecol. 2007;110:1279-1289.

30. Prasad P, Powell MC. Prospective observational study of thermablate endometrial ablation system as an outpatient procedure. J Minim Invasive Gynecol. 2008;15:476-479.

31. University of California, San Francisco. General prevention and screening. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-screening. Accessed June 24, 2015.

32. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995;82:341.

33. Meriggiola MC, Gava G. Endocrine care of transpeople part II: a review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83:607-615.

34. University of California, San Francisco. Surgical options. UCSF Center of Excellence for Transgender Health. Available at: http://transhealth.ucsf.edu/trans?page=protocol-surgery. Accessed December 12, 2015.

Issue
The Journal of Family Practice - 65(7)
Issue
The Journal of Family Practice - 65(7)
Page Number
450-452,457-461
Page Number
450-452,457-461
Publications
Publications
Topics
Article Type
Display Headline
Transgender patients: Providing sensitive care
Display Headline
Transgender patients: Providing sensitive care
Legacy Keywords
transgender, WPATH, World Professional Association for Transgender Health, female-to-male transition, male-to-female transition, LGBTQ, men's health, women's health, practice management, Abbas Hyderi, Joseph Angel, Morgan Madison, L. Amanda Perry, Leila Hagshenas
Legacy Keywords
transgender, WPATH, World Professional Association for Transgender Health, female-to-male transition, male-to-female transition, LGBTQ, men's health, women's health, practice management, Abbas Hyderi, Joseph Angel, Morgan Madison, L. Amanda Perry, Leila Hagshenas
Sections
Disallow All Ads
Article PDF Media

What are safe sleeping arrangements for infants?

Article Type
Changed
Mon, 01/14/2019 - 11:18
Display Headline
What are safe sleeping arrangements for infants?
EVIDENCE-BASED ANSWER

Non-supine sleep position and parental tobacco use are known risk factors for sudden infant death syndrome (SIDS). Recent studies show that co-sleeping (bed sharing) slightly increases the overall risk of SIDS (strength of recommendation [SOR]: B) and is greatest for infants less than 11 weeks old (SOR: B). The relationship between bed sharing and SIDS is strongest for infants whose parents use tobacco (SOR: B). Infants who sleep in a room separate from their caregivers or on a couch or an armchair are at increased risk for SIDS (SOR: B). Using bedding accessories such as duvets or pillows may increase an infant’s risk of SIDS (SOR: B).

CLINICAL COMMENTARY

Despite its weakness, counsel families based on what evidence is available
Perry Brown, MD, FAAP
Family Medicine Residency of Idaho, Boise; University of Washington School of Medicine, Seattle

This Clinical Inquiry reviews evidence about one of the most controversial and emotion-laden issues of infancy—where should baby sleep? Of course a parent wants to minimize the risk of SIDS, and this review has some evidence of how to accomplish this.

However, often there are pragmatic obstacles to an ideal sleeping arrangement for an infant. One obstacle is exhaustion. Parents are awake multiple times per night with a young infant, and having the infant bed-share is often easier and more efficient for breastfeeding mothers. Poverty is another obstacle—the family may be unable to afford a crib or bassinet. There can also be cultural obstacles, in that certain cultures traditionally bed-share with infants and children. Physicians are deterred from addressing bed-sharing with families, because the discussion is often lengthy and the family is sometimes defensive.

Despite generally weak evidence on this topic, we must counsel families based on what evidence is available, and not shy away from this discussion. Few things are worse than retrospectively wondering if a case of SIDS could have been prevented.

 

Evidence summary

SIDS is defined as the sudden death of an infant aged <1 year of age that remains unexplained after a thorough investigation. The SIDS mortality rate is 0.57 per 1000 infants, with peak incidence among 1- to 5-month-olds.1 Non-supine sleep position and parental tobacco use are established risk factors for SIDS and therefore are not explicitly addressed in this review. Using the 9 best-designed case-control studies published to date, each of which used multivariate analysis to control for infant sleep position and parental tobacco use (among other confounders), we evaluated co-sleeping, room sharing, sleep surfaces, and bedding accessories as risk factors for SIDS (TABLE).

TABLE
Sleeping arrangements and their relationship to SIDS

SLEEP ARRANGEMENTRISK ESTIMATE*
Co-sleeping2-10Overall OR: 2.0 (1.2–3.3)4 to 16.47 (3.72–72.75)9
 OR if parent is smoker: 4.55 (2.63–7.88)10 to 17.7 (10.3–20.0)8
 OR if parent is nonsmoker: 0.98 (0.44–2.18)10 to 2.20 (0.99–4.91)7
Sleeping in separate rooms5,6,8,11OR: 3.13 (1.82–5.26)8 to 10.49 (4.26–25.89)5
Sleeping on couch or chair4-6,955 non-bed sleepers among 772 total SIDS cases (7.1%)
vs 8 non-bed sleepers among 1854 total controls (0.4%)
Soft bedding accessories4,7-9OR for use of pillow: 1.03 (0.66–1.59)7 to 2.8 (1.3–6.2)4
 OR for use of duvet: 1.32 (0.41–4.15)9 vs 1.82 (1.30–2.58)8
*All studies used multivariate analyses and controlled for tobacco use and infant sleep position. Risk estimates are lowest to highest OR with 95% CI (unless otherwise specified).
†Aggregated data from 4 studies given small numbers.
SIDS, sudden infant death syndrome; OR, odds ratio; CI, confidence interval.

A number of factors complicated this review. First, although all studies evaluated infants through 1 year of age, some excluded infants <7 days or <28 days old. Second, studies examined different sleep periods; 2 focused on usual sleeping arrangements,2,3 5 on sleeping arrangement immediately prior to death,4-8 and 2 evaluated both usual and last sleep arrangements.9,10 Third, variations in definitions of each risk factor and differences in the confounders controlled for made comparing studies challenging. Fourth, given the difficulty in studying infant deaths, the best evidence available comes from case-control studies.

Co-sleeping. Overall, 5 of 6 studies demonstrated co-sleeping to be an independent risk factor for SIDS (odds ratio [OR]=2.0–16.5),2,4-7,9 especially for infants younger than 11 weeks old.6,8 Four stratified analyses indicate that the risk of co-sleeping is greatest among infants of smokers (OR=4.6–17.7) as compared with infants of nonsmokers (OR=1.0–2.2).3,7,8,10 Some descriptive studies suggest potential benefits of co-sleeping, such as improved breastfeeding and maternal-infant bonding, but these benefits have not been quantified.1

 

 

 

Room sharing. Three of 4 studies found that infants sleeping in separate rooms from their caregivers had a 3-fold increased risk of SIDS,5,6,11 while the fourth study found a 10-fold increased risk.8 One study found the risk was present in infants less than 20 weeks, but was inconclusive for those greater than 20 weeks.11

Sleep surface. All 4 studies evaluating sleep surface found a significantly increased risk of SIDS for infants sleeping on sofas or armchairs compared with infants sleeping in beds or cribs. Fifty-five of 772 total cases (7.1%) from the 4 studies slept on a non-bed surface compared with 8 of 1854 controls (0.4%).4-6,9

Bedding accessories. Two of 3 studies found pillow use unrelated to SIDS.4,7,9 The larger of 2 studies on duvet use found it to be a risk factor for SIDS (OR=1.82).8

Recommendations from others

The American Academy of Pediatrics recommends that infants should sleep supine in the same room, but not the same bed, as their caregivers, while on a firm surface without bedding accessories. They should never sleep on a couch or armchair. Infants may be brought into bed briefly for feeding or comforting. Parents should be encouraged to quit smoking.10

References

1. American Academy of Pediatrics. Task Force on Infant Sleep Position and SIDS. Changing concepts of SIDS: Implications for infant sleeping environment and sleep position. Pediatrics 2000;105:650-656.

2. Brooke H, Gibson A, Tappin D, Brown H. Case-control study of SIDS in Scotland, 1992–5. BMJ 1997;314:1516-1520.

3. Mitchell EA, Tuohy PG, Brunt JM, et al. Risk factors for SIDS following the prevention campaign in New Zealand: A prospective study. Pediatrics 1997;100:835-840.

4. Hauck FR, Herman SM, Donovan M, et al. Sleep environment and the risk of SIDS in an urban population: The Chicago infant mortality study. Pediatrics 2003;111:1207-1214.

5. Blair PS, Fleming PJ, Smith IJ, et al. Babies sleeping with parents: Case-control study of factors influencing the risk of SIDS. BMJ 1999;319:1457-1461.

6. Tappin D, Ecob R, Brooke H. Bedsharing, roomsharing, and SIDS in Scotland: A case-control study. J Pediatr 2005;147:32-37.

7. Vennemann MM, Findeisen M, Butterfass-Bahloul T, et al. Modifiable risk factors for SIDS in Germany: Results of GeSID. Acta Paediatrica 2005;94:655-660.

8. Carpenter RG, Irgens LM, Blair PS, et al. Sudden unexplained infant death in 20 regions in Europe: Case control study. Lancet 2004;363:185-191.

9. McGarvey C, McDonnell M, Chong A, et al. Factors relating to the infant’s last sleep environment in SIDS in the Republic of Ireland. Arch Dis Child 2003;88:1058-1064.

10. Scragg R, Mitchell EA, Taylor BJ, et al. Bed sharing, smoking, and alcohol in SIDS. BMJ 1993;307:1312-1318.

11. Scragg RK, Mitchell EA, Stewart AW, et al. Infant room-sharing and prone sleep position in SIDS. Lancet 1996;347:7-12.

Article PDF
Author and Disclosure Information

Michelle R. Adler, MD, MPH
Department of Family Medicine, Oregon Health & Science University

Abbas Hyderi, MD, MPH
Department of Family Medicine, University of Illinois at Chicago

Andrew Hamilton, MS, MLS
Reference Librarian, Oregon Health & Science University

Issue
The Journal of Family Practice - 55(12)
Publications
Topics
Page Number
1083-1087
Sections
Author and Disclosure Information

Michelle R. Adler, MD, MPH
Department of Family Medicine, Oregon Health & Science University

Abbas Hyderi, MD, MPH
Department of Family Medicine, University of Illinois at Chicago

Andrew Hamilton, MS, MLS
Reference Librarian, Oregon Health & Science University

Author and Disclosure Information

Michelle R. Adler, MD, MPH
Department of Family Medicine, Oregon Health & Science University

Abbas Hyderi, MD, MPH
Department of Family Medicine, University of Illinois at Chicago

Andrew Hamilton, MS, MLS
Reference Librarian, Oregon Health & Science University

Article PDF
Article PDF
EVIDENCE-BASED ANSWER

Non-supine sleep position and parental tobacco use are known risk factors for sudden infant death syndrome (SIDS). Recent studies show that co-sleeping (bed sharing) slightly increases the overall risk of SIDS (strength of recommendation [SOR]: B) and is greatest for infants less than 11 weeks old (SOR: B). The relationship between bed sharing and SIDS is strongest for infants whose parents use tobacco (SOR: B). Infants who sleep in a room separate from their caregivers or on a couch or an armchair are at increased risk for SIDS (SOR: B). Using bedding accessories such as duvets or pillows may increase an infant’s risk of SIDS (SOR: B).

CLINICAL COMMENTARY

Despite its weakness, counsel families based on what evidence is available
Perry Brown, MD, FAAP
Family Medicine Residency of Idaho, Boise; University of Washington School of Medicine, Seattle

This Clinical Inquiry reviews evidence about one of the most controversial and emotion-laden issues of infancy—where should baby sleep? Of course a parent wants to minimize the risk of SIDS, and this review has some evidence of how to accomplish this.

However, often there are pragmatic obstacles to an ideal sleeping arrangement for an infant. One obstacle is exhaustion. Parents are awake multiple times per night with a young infant, and having the infant bed-share is often easier and more efficient for breastfeeding mothers. Poverty is another obstacle—the family may be unable to afford a crib or bassinet. There can also be cultural obstacles, in that certain cultures traditionally bed-share with infants and children. Physicians are deterred from addressing bed-sharing with families, because the discussion is often lengthy and the family is sometimes defensive.

Despite generally weak evidence on this topic, we must counsel families based on what evidence is available, and not shy away from this discussion. Few things are worse than retrospectively wondering if a case of SIDS could have been prevented.

 

Evidence summary

SIDS is defined as the sudden death of an infant aged <1 year of age that remains unexplained after a thorough investigation. The SIDS mortality rate is 0.57 per 1000 infants, with peak incidence among 1- to 5-month-olds.1 Non-supine sleep position and parental tobacco use are established risk factors for SIDS and therefore are not explicitly addressed in this review. Using the 9 best-designed case-control studies published to date, each of which used multivariate analysis to control for infant sleep position and parental tobacco use (among other confounders), we evaluated co-sleeping, room sharing, sleep surfaces, and bedding accessories as risk factors for SIDS (TABLE).

TABLE
Sleeping arrangements and their relationship to SIDS

SLEEP ARRANGEMENTRISK ESTIMATE*
Co-sleeping2-10Overall OR: 2.0 (1.2–3.3)4 to 16.47 (3.72–72.75)9
 OR if parent is smoker: 4.55 (2.63–7.88)10 to 17.7 (10.3–20.0)8
 OR if parent is nonsmoker: 0.98 (0.44–2.18)10 to 2.20 (0.99–4.91)7
Sleeping in separate rooms5,6,8,11OR: 3.13 (1.82–5.26)8 to 10.49 (4.26–25.89)5
Sleeping on couch or chair4-6,955 non-bed sleepers among 772 total SIDS cases (7.1%)
vs 8 non-bed sleepers among 1854 total controls (0.4%)
Soft bedding accessories4,7-9OR for use of pillow: 1.03 (0.66–1.59)7 to 2.8 (1.3–6.2)4
 OR for use of duvet: 1.32 (0.41–4.15)9 vs 1.82 (1.30–2.58)8
*All studies used multivariate analyses and controlled for tobacco use and infant sleep position. Risk estimates are lowest to highest OR with 95% CI (unless otherwise specified).
†Aggregated data from 4 studies given small numbers.
SIDS, sudden infant death syndrome; OR, odds ratio; CI, confidence interval.

A number of factors complicated this review. First, although all studies evaluated infants through 1 year of age, some excluded infants <7 days or <28 days old. Second, studies examined different sleep periods; 2 focused on usual sleeping arrangements,2,3 5 on sleeping arrangement immediately prior to death,4-8 and 2 evaluated both usual and last sleep arrangements.9,10 Third, variations in definitions of each risk factor and differences in the confounders controlled for made comparing studies challenging. Fourth, given the difficulty in studying infant deaths, the best evidence available comes from case-control studies.

Co-sleeping. Overall, 5 of 6 studies demonstrated co-sleeping to be an independent risk factor for SIDS (odds ratio [OR]=2.0–16.5),2,4-7,9 especially for infants younger than 11 weeks old.6,8 Four stratified analyses indicate that the risk of co-sleeping is greatest among infants of smokers (OR=4.6–17.7) as compared with infants of nonsmokers (OR=1.0–2.2).3,7,8,10 Some descriptive studies suggest potential benefits of co-sleeping, such as improved breastfeeding and maternal-infant bonding, but these benefits have not been quantified.1

 

 

 

Room sharing. Three of 4 studies found that infants sleeping in separate rooms from their caregivers had a 3-fold increased risk of SIDS,5,6,11 while the fourth study found a 10-fold increased risk.8 One study found the risk was present in infants less than 20 weeks, but was inconclusive for those greater than 20 weeks.11

Sleep surface. All 4 studies evaluating sleep surface found a significantly increased risk of SIDS for infants sleeping on sofas or armchairs compared with infants sleeping in beds or cribs. Fifty-five of 772 total cases (7.1%) from the 4 studies slept on a non-bed surface compared with 8 of 1854 controls (0.4%).4-6,9

Bedding accessories. Two of 3 studies found pillow use unrelated to SIDS.4,7,9 The larger of 2 studies on duvet use found it to be a risk factor for SIDS (OR=1.82).8

Recommendations from others

The American Academy of Pediatrics recommends that infants should sleep supine in the same room, but not the same bed, as their caregivers, while on a firm surface without bedding accessories. They should never sleep on a couch or armchair. Infants may be brought into bed briefly for feeding or comforting. Parents should be encouraged to quit smoking.10

EVIDENCE-BASED ANSWER

Non-supine sleep position and parental tobacco use are known risk factors for sudden infant death syndrome (SIDS). Recent studies show that co-sleeping (bed sharing) slightly increases the overall risk of SIDS (strength of recommendation [SOR]: B) and is greatest for infants less than 11 weeks old (SOR: B). The relationship between bed sharing and SIDS is strongest for infants whose parents use tobacco (SOR: B). Infants who sleep in a room separate from their caregivers or on a couch or an armchair are at increased risk for SIDS (SOR: B). Using bedding accessories such as duvets or pillows may increase an infant’s risk of SIDS (SOR: B).

CLINICAL COMMENTARY

Despite its weakness, counsel families based on what evidence is available
Perry Brown, MD, FAAP
Family Medicine Residency of Idaho, Boise; University of Washington School of Medicine, Seattle

This Clinical Inquiry reviews evidence about one of the most controversial and emotion-laden issues of infancy—where should baby sleep? Of course a parent wants to minimize the risk of SIDS, and this review has some evidence of how to accomplish this.

However, often there are pragmatic obstacles to an ideal sleeping arrangement for an infant. One obstacle is exhaustion. Parents are awake multiple times per night with a young infant, and having the infant bed-share is often easier and more efficient for breastfeeding mothers. Poverty is another obstacle—the family may be unable to afford a crib or bassinet. There can also be cultural obstacles, in that certain cultures traditionally bed-share with infants and children. Physicians are deterred from addressing bed-sharing with families, because the discussion is often lengthy and the family is sometimes defensive.

Despite generally weak evidence on this topic, we must counsel families based on what evidence is available, and not shy away from this discussion. Few things are worse than retrospectively wondering if a case of SIDS could have been prevented.

 

Evidence summary

SIDS is defined as the sudden death of an infant aged <1 year of age that remains unexplained after a thorough investigation. The SIDS mortality rate is 0.57 per 1000 infants, with peak incidence among 1- to 5-month-olds.1 Non-supine sleep position and parental tobacco use are established risk factors for SIDS and therefore are not explicitly addressed in this review. Using the 9 best-designed case-control studies published to date, each of which used multivariate analysis to control for infant sleep position and parental tobacco use (among other confounders), we evaluated co-sleeping, room sharing, sleep surfaces, and bedding accessories as risk factors for SIDS (TABLE).

TABLE
Sleeping arrangements and their relationship to SIDS

SLEEP ARRANGEMENTRISK ESTIMATE*
Co-sleeping2-10Overall OR: 2.0 (1.2–3.3)4 to 16.47 (3.72–72.75)9
 OR if parent is smoker: 4.55 (2.63–7.88)10 to 17.7 (10.3–20.0)8
 OR if parent is nonsmoker: 0.98 (0.44–2.18)10 to 2.20 (0.99–4.91)7
Sleeping in separate rooms5,6,8,11OR: 3.13 (1.82–5.26)8 to 10.49 (4.26–25.89)5
Sleeping on couch or chair4-6,955 non-bed sleepers among 772 total SIDS cases (7.1%)
vs 8 non-bed sleepers among 1854 total controls (0.4%)
Soft bedding accessories4,7-9OR for use of pillow: 1.03 (0.66–1.59)7 to 2.8 (1.3–6.2)4
 OR for use of duvet: 1.32 (0.41–4.15)9 vs 1.82 (1.30–2.58)8
*All studies used multivariate analyses and controlled for tobacco use and infant sleep position. Risk estimates are lowest to highest OR with 95% CI (unless otherwise specified).
†Aggregated data from 4 studies given small numbers.
SIDS, sudden infant death syndrome; OR, odds ratio; CI, confidence interval.

A number of factors complicated this review. First, although all studies evaluated infants through 1 year of age, some excluded infants <7 days or <28 days old. Second, studies examined different sleep periods; 2 focused on usual sleeping arrangements,2,3 5 on sleeping arrangement immediately prior to death,4-8 and 2 evaluated both usual and last sleep arrangements.9,10 Third, variations in definitions of each risk factor and differences in the confounders controlled for made comparing studies challenging. Fourth, given the difficulty in studying infant deaths, the best evidence available comes from case-control studies.

Co-sleeping. Overall, 5 of 6 studies demonstrated co-sleeping to be an independent risk factor for SIDS (odds ratio [OR]=2.0–16.5),2,4-7,9 especially for infants younger than 11 weeks old.6,8 Four stratified analyses indicate that the risk of co-sleeping is greatest among infants of smokers (OR=4.6–17.7) as compared with infants of nonsmokers (OR=1.0–2.2).3,7,8,10 Some descriptive studies suggest potential benefits of co-sleeping, such as improved breastfeeding and maternal-infant bonding, but these benefits have not been quantified.1

 

 

 

Room sharing. Three of 4 studies found that infants sleeping in separate rooms from their caregivers had a 3-fold increased risk of SIDS,5,6,11 while the fourth study found a 10-fold increased risk.8 One study found the risk was present in infants less than 20 weeks, but was inconclusive for those greater than 20 weeks.11

Sleep surface. All 4 studies evaluating sleep surface found a significantly increased risk of SIDS for infants sleeping on sofas or armchairs compared with infants sleeping in beds or cribs. Fifty-five of 772 total cases (7.1%) from the 4 studies slept on a non-bed surface compared with 8 of 1854 controls (0.4%).4-6,9

Bedding accessories. Two of 3 studies found pillow use unrelated to SIDS.4,7,9 The larger of 2 studies on duvet use found it to be a risk factor for SIDS (OR=1.82).8

Recommendations from others

The American Academy of Pediatrics recommends that infants should sleep supine in the same room, but not the same bed, as their caregivers, while on a firm surface without bedding accessories. They should never sleep on a couch or armchair. Infants may be brought into bed briefly for feeding or comforting. Parents should be encouraged to quit smoking.10

References

1. American Academy of Pediatrics. Task Force on Infant Sleep Position and SIDS. Changing concepts of SIDS: Implications for infant sleeping environment and sleep position. Pediatrics 2000;105:650-656.

2. Brooke H, Gibson A, Tappin D, Brown H. Case-control study of SIDS in Scotland, 1992–5. BMJ 1997;314:1516-1520.

3. Mitchell EA, Tuohy PG, Brunt JM, et al. Risk factors for SIDS following the prevention campaign in New Zealand: A prospective study. Pediatrics 1997;100:835-840.

4. Hauck FR, Herman SM, Donovan M, et al. Sleep environment and the risk of SIDS in an urban population: The Chicago infant mortality study. Pediatrics 2003;111:1207-1214.

5. Blair PS, Fleming PJ, Smith IJ, et al. Babies sleeping with parents: Case-control study of factors influencing the risk of SIDS. BMJ 1999;319:1457-1461.

6. Tappin D, Ecob R, Brooke H. Bedsharing, roomsharing, and SIDS in Scotland: A case-control study. J Pediatr 2005;147:32-37.

7. Vennemann MM, Findeisen M, Butterfass-Bahloul T, et al. Modifiable risk factors for SIDS in Germany: Results of GeSID. Acta Paediatrica 2005;94:655-660.

8. Carpenter RG, Irgens LM, Blair PS, et al. Sudden unexplained infant death in 20 regions in Europe: Case control study. Lancet 2004;363:185-191.

9. McGarvey C, McDonnell M, Chong A, et al. Factors relating to the infant’s last sleep environment in SIDS in the Republic of Ireland. Arch Dis Child 2003;88:1058-1064.

10. Scragg R, Mitchell EA, Taylor BJ, et al. Bed sharing, smoking, and alcohol in SIDS. BMJ 1993;307:1312-1318.

11. Scragg RK, Mitchell EA, Stewart AW, et al. Infant room-sharing and prone sleep position in SIDS. Lancet 1996;347:7-12.

References

1. American Academy of Pediatrics. Task Force on Infant Sleep Position and SIDS. Changing concepts of SIDS: Implications for infant sleeping environment and sleep position. Pediatrics 2000;105:650-656.

2. Brooke H, Gibson A, Tappin D, Brown H. Case-control study of SIDS in Scotland, 1992–5. BMJ 1997;314:1516-1520.

3. Mitchell EA, Tuohy PG, Brunt JM, et al. Risk factors for SIDS following the prevention campaign in New Zealand: A prospective study. Pediatrics 1997;100:835-840.

4. Hauck FR, Herman SM, Donovan M, et al. Sleep environment and the risk of SIDS in an urban population: The Chicago infant mortality study. Pediatrics 2003;111:1207-1214.

5. Blair PS, Fleming PJ, Smith IJ, et al. Babies sleeping with parents: Case-control study of factors influencing the risk of SIDS. BMJ 1999;319:1457-1461.

6. Tappin D, Ecob R, Brooke H. Bedsharing, roomsharing, and SIDS in Scotland: A case-control study. J Pediatr 2005;147:32-37.

7. Vennemann MM, Findeisen M, Butterfass-Bahloul T, et al. Modifiable risk factors for SIDS in Germany: Results of GeSID. Acta Paediatrica 2005;94:655-660.

8. Carpenter RG, Irgens LM, Blair PS, et al. Sudden unexplained infant death in 20 regions in Europe: Case control study. Lancet 2004;363:185-191.

9. McGarvey C, McDonnell M, Chong A, et al. Factors relating to the infant’s last sleep environment in SIDS in the Republic of Ireland. Arch Dis Child 2003;88:1058-1064.

10. Scragg R, Mitchell EA, Taylor BJ, et al. Bed sharing, smoking, and alcohol in SIDS. BMJ 1993;307:1312-1318.

11. Scragg RK, Mitchell EA, Stewart AW, et al. Infant room-sharing and prone sleep position in SIDS. Lancet 1996;347:7-12.

Issue
The Journal of Family Practice - 55(12)
Issue
The Journal of Family Practice - 55(12)
Page Number
1083-1087
Page Number
1083-1087
Publications
Publications
Topics
Article Type
Display Headline
What are safe sleeping arrangements for infants?
Display Headline
What are safe sleeping arrangements for infants?
Sections
PURLs Copyright

Evidence-based answers from the Family Physicians Inquiries Network

Disallow All Ads
Alternative CME
Article PDF Media